Novel trypanosomal vaccine

Abstract

The present invention relates to a trypanosomal vaccine comprising an FLA1 binding protein, as well as to pharmaceutical compositions comprising said vaccine and their uses in vaccination to prevent o

Description

FIELD OF THE INVENTION The invention relates to a trypanosomal vaccine, to pharmaceutical compositions comprising said vaccine and to their uses in vaccination to prevent or treat trypanosomal infection in a mammal. BACKGROUND OF THE INVENTION The livelihoods of millions of people living in Africa are at risk due to infectious diseases that affect the health of livestock animals that provide them with essential food, milk, clothing and draught power. One major livestock disease is animal African trypanosomiasis (AAT) which is caused by blood-dwelling Trypanosome parasites that affect many important farm animals including cattle, goats, sheep, horses, and pigs. AAT is endemic from the Southern edge of the Sahara to Zimbabwe / Mozambique and is estimated to cause annual productivity losses of over $1 billion, representing a major barrier for the socioeconomic advancement of many African countries. Such is the impact of this disease that the United Nations Food and Agricultural Organisation consider it to “lie at the heart of Africa’s struggle against poverty”. The disease is mainly caused by two species of trypanosome: T. congolense and T. vivax which are transmitted through the bite of an infected tsetse fly. The few drugs available for AAT are not satisfactory: they cause serious side effects, and parasite resistance to these drugs is increasing. Importantly, even if new effective drugs were developed, these trypanosome parasites are endemic in wild animals meaning there would be little chance of eradicating the disease, and so livestock animals would require constant monitoring and treatment. The best solution would be the deployment of an effective vaccine; however, vaccinating against trypanosome infections has long been considered unachievable because the surface of these parasites is immunologically protected by a highly abundant cell surface protein called the variable surface glycoprotein (VSG). VSGs comprise a large family of related but not identical proteins, and trypanosomes express a small number or even a single variant on their surface at any one time. Host antibodies to VSG alleles are able to kill parasites; however, individual parasites within a population of trypanosomes can switch between variants and those that have switched to an antigenically distinct variant are able to effectively evade the host immune response ensuring the survival of the population as a whole. One commonly-used strategy in the development of vaccines is to use inactivated or attenuated parasites, however, these vaccines are difficult to manufacture and can sometimes cause outbreaks if not appropriately attenuated. Modern vaccines, therefore, are typically purified recombinant proteins that can elicit protective immune responses and are consequently chemically defined. Leishmania is a related genus of trypanosomes which are responsible for the disease leishmaniasis. They are spread by sandflies of the genus Phiebotomus in the Old World, and of the genus Lutzomyia in the New World. At least 93 sandfly species are proven or probable vectors worldwide. Their primary hosts are vertebrates; Leishmania commonly infects hyraxes, canids, rodents, and humans. There is therefore a great need to provide an alternative and effective vaccine against trypanosomes such as the Trypanosoma and Leishmania species. SUMMARY OF THE INVENTION According to a first aspect of the invention, there is provided a trypanosomal vaccine comprising an FLA1 binding protein. According to a further aspect of the invention, there is provided a pharmaceutical composition comprising the trypanosomal vaccine as defined herein. According to a further aspect of the invention, there is provided a method of preventing or treating trypanosomal infection in a mammal which comprises administering to the mammal a therapeutically effective amount of the vaccine composition as defined herein. According to a further aspect of the invention, there is provided a method of inducing an immune response in a mammal, wherein the method includes administering to the mammal, an effective amount of the vaccine composition as defined herein. According to a further aspect of the invention, there is provided a kit of parts comprising a vaccine composition as defined herein, a medical instrument or other means for administering the vaccine composition and instructions for use. BRIEF DESCRIPTION OF THE FIGURES Figure 1: Expression and purification of the extracellular regions of TclL3000_0_35140 and Tcll_3000_0_17090. Proteins consisting of the entire ectodomains of TclL3000_0_35140 and TclL3000_0_17090 were expressed as a soluble recombinant protein in HEK293 cells and purified from spent tissue culture media using immobilised metal ion chromatography. Approximately one microgram of each purified protein was resolved by SDS- PAGE under reducing conditions. The protein migrated as a series of glycoforms around the expected mass. Figure 2: Vaccination with the ectodomains of Tcll_3000_0_35140 confers protection in a murine model of T. congolense infection. (A) Five animals were vaccinated with TclL3000_0_35140 (solid line, filled diamonds) show attenuated T. congolense parasitaemia relative to adjuvant-only control animals (dotted lines, open circles). Parasitaemia was quantified in each animal by bioluminescence using the firefly luciferase gene transgenically expressed by the T. congolense strain used and plotted as a function of time post-infection. Survival curves indicate when animals were withdrawn from the study. (B) Comparisons of the parasitaemia on the indicated days post-infection in the vaccinated and control animals. Data points represent individual animals and horizontal bar represents mean ± s.d. Comparisons were made using an one-way ANOVA with Dunnett’s multiple comparison test for statistical confidence where * P <0.01; “ P <0.001; **** P <0.00001. (C) Exemplar bioluminescence images of three control animals (numbers 1 to 3) and three vaccinated (numbers 4 to 6) on the indicated days post-infection. A cross indicates that the animal was removed from the study. Figure 3: Repeat vaccinations with an independent preparation of TclL3000_0_35140 in a larger cohort conforms vaccine effect in a murine model of T. congolense infection. (A) Fifteen animals were vaccinated with TclL3000_0_35140 (solid line filled diamonds) show attenuated T. congolense parasitaemia relative to adjuvant-only control animals (dotted lines open circles). Parasitaemia was quantified in each animal by bioluminescence using the firefly luciferase gene transgenically expressed by the T. congelense strain used and plotted as a function of time post-infection. Survival curves indicate when animals were withdrawn from the study. (B) Comparisons of the parasitaemia on the indicated days post-infection in the vaccinated and control animals. Data points represent individual animals and horizontal bar represents mean ± s.d. Comparisons were made using the student t-test where statistical confidence is indicated as **** P <0.00001. Figure 4: Vaccination with the ectodomains of TclL3000_0_17090 confers protection in a murine model of T. congolense infection. (A) Five animals were vaccinated with TclL3000_0_17090 (solid line, filled diamonds) show attenuated T. congolense parasitaemia relative to adjuvant-only control animals (dotted lines, open circles). Parasitaemia was quantified in each animal by bioluminescence using the firefly luciferase gene transgenically expressed by the T. congolense strain used and plotted as a function of time post-infection. Survival curves indicate when animals were withdrawn from the study. (B) Comparisons of the parasitaemia on the indicated days post-infection in the vaccinated and control animals. Data points represent individual animals and horizontal bar represents mean ± s.d. Comparisons were made using a one-way ANOVA with Dunnett’s multiple comparison test for statistical confidence where * P <0.01; ** P <0.001; **** P <0.00001. (C) Exemplar bioluminescence images of three control animals (numbers 1 to 3) and three vaccinated (numbers 4 to 6) on the indicated days post-infection. A cross indicates that the animal was removed from the study. Figure 5: Passive transfer of immunity to Trypanosoma congolense infections with anti-TclL3000_0_17090 immune sera. Mice received three doses of 100 or 200 microlitres of immune sera from animals immunised with the ectodomain of TclL3000_0_17090 or control sera and challenged with a bioluminescent T. congolense parasite. Mice dosed with immune sera showed a dose-dependent reduction in parasitaemia compared to those receiving control sera. Bars indicate mean ± SD, groups were compared by one-way ANOVA with Sidak post-hoc test * P <0.01, **** P <0.00001. Figure 6: Mice vaccinated with recombinant TclL3000_0_35140 representing the “Savannah” strain of T. congolense are able to cross-protect against challenge with a “Forest-type” strain. (A) Nine mice were immunized with purified soluble TclL3000_0_35140 recombinant protein adjuvanted in Quil-A and challenged with “Forest-type” T. congolense strain called DIN80 (solid line, filled diamonds). Parasitaemia was quantified on the indicated days after parasite challenge by microscopy; controls are a cohort of eight animals treated with adjuvant only (dotted line, open circles). Vaccinated animals were partially protected from the infection compared to the control animals with one animal showing no evidence of parasitaemia up until day 22. (B) Statistical comparison of the data shown in (A) which compares the parasitaemia in the TclL3000_0_35140-vaccinated animals (filled diamonds) to controls (open circles) on the indicated days. Bars indicate mean ± SD, groups were compared by an unpaired t test; ns = not significant, P <0.0001, **** P <0.00001. Data points represent individual animals and grey shading indicates the limits of detection. Figure 7: Mice vaccinated with both recombinant IFX and Tcll_3000_0_17090 are able to control infections from both T. vivax and T. congolense. (A) T. vivax challenge. Mice were vaccinated with purified soluble IFX (dot-dash line, filled circles) or a combination of both IFX and TclL3000_0_17090 in a co-administration protocol using Quil-A as an adjuvant (solid line, filled squares) and challenged with a transgenic luciferase-expressing T. vivax line. Vaccinated animals from both groups were partially protected from the infection compared to the control animals (dotted line, unfilled circles) with seven out of ten IFX-alone vaccinated animals, and five out of ten IFX - TclL3000_0_17090 vaccinated animals showing evidence of sterile protection. (B) T. congolense challenge. Vaccinated mice were challenged with a bioluminescent T. congolense parasite with those animals vaccinated with IFX-alone (dotdash line, filled circles) showing no evidence of protection as expected. Animals vaccinated with either TclL3000_0_17090 alone (dashed line, unfilled diamonds) or both IFX and TclL3000_0_17090 (solid line, filled squares) showed evidence of protection against T. congolense infection compared to controls (dotted line, cross-filled diamonds). Data points represent individual animals and grey shading indicates the limits of detection. DETAILED DESCRIPTION OF THE INVENTION According to a first aspect of the invention, there is provided a trypanosomal vaccine comprising an FLA1 binding protein. References herein to FLA1 binding protein refer to the flagellum adhesion protein 1 (FLA1), a glycosylated, transmembrane protein essential for flagellum attachment and cell division. The present invention relates to the identification of non-variant cell surface T. congolense proteins, which, when used in the context of a vaccine can elicit protective immune responses. Using the genome sequence to identify potential candidates, a pair of related vaccine target antigens have been identified which, when produced as a purified recombinant protein and administered with an appropriate immunostimulatory adjuvant, confers protection to T. congolense infections in mice. The key finding of the invention is recognition that these two candidate vaccines are both FLA1 binding proteins. The results presented herein indicate that these non-variant parasite proteins will be an important component of a vaccine to prevent AAT in livestock animals. This finding has applicability to vaccines in other species which contain orthologs of FLA1 binding proteins, such as Leishmania. In one embodiment, the FLA1 binding protein comprises the amino acid sequence as set forth in SEQ ID NO: 1, or a protein having at least 90% sequence identity to said amino acid sequence, or a fragment of said amino acid sequence thereof, or a nucleic acid molecule encoding said protein. References herein to the amino acid sequence set forth in SEQ ID NO: 1 refer to: AVAHVKRNRRVETVAGAYGLTGMVDGVPPDSRLSSPMAICRGRTADEILVGTASGLRTYS RSSGELGTLFTSSVKVVGGSTGGSAYGNPRSCVHRGIDNSSVIYFVDGQKDVKYYKNNEV LSKDTVANASLTAMTIFGGSLYMTDQINKALVTCKLSADGAPHDCLSKKKLNDTCGFNTFTG ITSTAKGIFIAGQGSTTPGNICWIGLDDTTVTKLGQGEYVDVSSTSSGDLYAVSKTQIFHLEP AGSAPQLKTVAGVKGTPCLPTPDGEDIRFCELNKILAIADHELYVTSERSHLLRAVILPPVRV QAVFSGRPVPVGYPEGDTLDWIVENLVKDVNEALQTTESLIDPSTVYVDPDTWTTRFVALV QQSDFDDAATERALGEGNYTYITAALDEYYNETDQAVYMDSVMVPYCSEAALDAIRRRIAE EARRVLDFPLIYADMPVELEGSGVENVTMVKLLMPASFNNETVSELLEAADLTGFAHSAIKE MRGGETRVSWLPNPPFNFSGVTPDVDQDIRWYVHGNVMKQLDICEKLNAKGAAPAPEPV EDGNESGGGWYTGEFCQSSITNRTETQNLKPPYDQKNTYEIFLPNKYDFNASWCVDIVD WRELNDWLSNVTAGSHIEDASWCGQGCII (SEQ ID NO: 1). The amino acid sequence of SEQ ID NO: 1 corresponds to the ectodomain of a cell surface T. congolense protein known as TclL3000_0_17090. The full length amino acid sequence of TclL3000_0_17090 is shown below: M RTGRALQVLLHATIISLGLVECAVAHVKRNRRVETVAGAYGLTGMVDGVPPDSRLSSPMA ICRGRTADEILVGTASGLRTYSRSSGELGTLFTSSVKVVGGSTGGSAYGNPRSCVHRGIDN SSVIYFVDGQKDVKYYKNNEVLSKDTVANASLTAMTIFGGSLYMTDQINKALVTCKLSADGA PHDCLSKKKLNDTCGFNTFTGITSTAKGIFIAGQGSTTPGNICWIGLDDTTVTKLGQGEYVD VSSTSSGDLYAVSKTQIFHLEPAGSAPQLKTVAGVKGTPCLPTPDGEDIRFCELNKILAIADH ELYVTSERSHLLRAVILPPVRVQAVFSGRPVPVGYPEGDTLDWIVENLVKDVNEALQTTESL IDPSTVYVDPDTWTTRFVALVQQSDFDDAATERALGEGNYTYITAALDEYYNETDQAVYMD SVMVPYCSEAALDAIRRRIAEEARRVLDFPLIYADMPVELEGSGVENVTMVKLLMPASFNNE TVSELLEAADLTGFAHSAIKEMRGGETRVSWLPNPPFNFSGVTPDVDQDIRWYVHGNVIVIK QLDICEKLNAKGAAPAPEPVEDGNESGGGWYTGEFCQSSITNRTETQNLKPPYDQKNTYE IFLPNKYDFNASWCVDIVDWRELNDWLSNVTAGSHIEDASWCGQGCIIALAWGALLTTGLV VVAWLTSKRRRLAAWAPPRPKFVSATEDEED (SEQ ID NO: 2) wherein the underlined portion represents the ectodomain region of TclL3000_0_17090. Data is presented herein which surprisingly shows that vaccinating animals with a recombinant protein comprising the entire ectodomain of TclL3000_0_17090 T. congolense cell surface protein confers protection in a mouse model of infection demonstrating that this protein could be an effective subunit vaccine and therefore represents a very attractive candidate for preventing or treating T. congolense infection. In an alternative embodiment, the FLA1 binding protein comprises the amino acid sequence as set forth in SEQ ID NO: 3, or a protein having at least 90% sequence identity to said amino acid sequence, or a fragment of said amino acid sequence thereof, or a nucleic acid molecule encoding said protein. References herein to the amino acid sequence set forth in SEQ ID NO: 3 refer to: HVKRNRRVETVAGAYGLTGMVDGVPPDSRLSSPMAICRGRTADEILVGTASGLRTYSRSS GELGTLFTSSVKVVGGSTGGSAYGNPRSCVHRGIDNSSVIYFVDGQKDVKYYKNNEVLSK DTVANASLTAMTIFGGSLYMTDQINKALVTCKLSADGAPHDCLSKKKLNDTCGFNTFTGITS TAKGIFIAGQGSTTPGNICWIGLDDTTVTKLGQGEYVDVSSTSSGDLYAVSKTQIFHLEPAG SAPQLKTVAGVKGTPCLPTPDGEDIRFCELNKILAIADHELYVTSERSHLLRAVILPPVRVQA VFSGRPVPVGYPEGDTLDWIVENLVKDVNEALQTTESLIDPSTVYVDPDTWTTRFVALVQQ SDFDDAATERALGEGNYTYITAALDEYYNETDQAVYMDSVMVPYCSEAALDAIRRKIAEEAR RVLDFPLIYADMPVELEGSGAENVTMVKLLMPASFNNETVSELLEAADLTGFAHSAIKEMRG GETRVSVVLPNPPFNFSGVTPDVDQDIRWYVHGNVMKQLDICEKLNAKGAAPAPEPVEDS NESGGGVVYTGEFCQSSITNRTETQNLKPPYDQKNTYEIFLPNKYDFNASWCVDIVDWREL NDWLSNVTVGSHIEDASWCGQGCI (SEQ ID NO: 3). The amino acid sequence of SEQ ID NO: 3 corresponds to the ectodomain of a cell surface T. congolense protein known as TclL3000_0_35140. The full length amino acid sequence of TclL3000_0_35140 is shown below: M RTGRALQLLLHATIIFLGLVECAVAHVKRNRRVETVAGAYGLTGMVDGVPPDSRLSSPMAI CRGRTADEILVGTASGLRTYSRSSGELGTLFTSSVKVVGGSTGGSAYGNPRSCVHRGIDNS SVIYFVDGQKDVKYYKNNEVLSKDTVANASLTAMTIFGGSLYMTDQINKALVTCKLSADGAP HDCLSKKKLNDTCGFNTFTGITSTAKGIFIAGQGSTTPGNICWIGLDDTTVTKLGQGEYVDV SSTSSGDLYAVSKTQIFHLEPAGSAPQLKTVAGVKGTPCLPTPDGEDIRFCELNKILAIADHE LYVTSERSHLLRAVILPPVRVQAVFSGRPVPVGYPEGDTLDWIVENLVKDVNEALQTTESLI DPSTVYVDPDTWTTRFVALVQQSDFDDAATERALGEGNYTYITAALDEYYNETDQAVYMD SVMVPYCSEAALDAIRRKIAEEARRVLDFPLIYADMPVELEGSGAENVTMVKLLMPASFNNE TVSELLEAADLTGFAHSAIKEMRGGETRVSVVLPNPPFNFSGVTPDVDQDIRWYVHGNVMK QLDICEKLNAKGAAPAPEPVEDSNESGGGVVYTGEFCQSSITNRTETQNLKPPYDQKNTYE IFLPNKYDFNASWCVDIVDWRELNDWLSNVTVGSHIEDASWCGQGCIIALAVVGALLTTGLV VVAWLTSKRRRLAAVVAPPRPKFVSATEDEED (SEQ ID NO: 4) wherein the underlined portion represents the ectodomain region of TclL3000_0_35140. Data is presented herein which surprisingly shows that vaccinating animals with a recombinant protein comprising the entire ectodomain of TclL3000_0_35140 T. congolense cell surface protein confers protection in a mouse model of infection demonstrating that this protein could be an effective subunit vaccine and therefore represents a very attractive candidate for preventing or treating T. congolense infection. It will be appreciated that references herein to “identity” are to be understood as meaning the percentage identity between two protein sequences, e.g.: SEQ ID NO: X and SEQ ID NO: 1 or SEQ ID NO: X and SEQ ID NO: 3, which is the sum of the common amino acids between aligned sequences SEQ ID NO: X and SEQ ID NO: 1 or SEQ ID NO: X and SEQ ID NO: 3, divided by the shorter length of either SEQ ID NO: X or SEQ ID NOs: 1 or 3, expressed as a percentage. In one embodiment, the protein of the invention has greater than 90% sequence identity with the ectodomain region of TclL3000_0_17090 (SEQ ID NO: 1), such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the ectodomain region of TclL3000_0_17090 (SEQ ID NO: 1). In an alternative embodiment, the protein of the invention has greater than 90% sequence identity with the ectodomain region of TclL3000_0_35140 (SEQ ID NO: 3), such as at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the ectodomain region of TclL3000_0_35140 (SEQ ID NO: 3). References herein to ‘fragment’ include, for example, functional fragments with a C-terminal truncation, or with an N-terminal truncation. Fragments are suitably greater than 10 amino acids in length, for example greater than 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490 or 500 amino acids in length. In a further embodiment, the protein of the invention consists of the amino acid sequence as set forth in SEQ ID NO: 1. In an alternative embodiment, the protein of the invention consists of the amino acid sequence as set forth in SEQ ID NO: 3. In an alternative embodiment, the vaccine comprises a nucleic acid molecule encoding said protein of the invention. References herein to “nucleic acid molecule” typically refers to DNA or RNA. In a further embodiment, the nucleic acid molecule comprises an oligonucleotide encoding said protein. References herein to “trypanosomal” refer to a genus of kinetoplastids (class Kinetoplastida), a monophyletic group of unicellular parasitic flagellate protozoa. The name is derived from the Greek trypano- (borer) and soma (body) because of their corkscrew-like motion. Most trypanosomes are heteroxenous (requiring more than one obligatory host to complete life cycle) and most are transmitted via a vector. The majority of species are transmitted by bloodfeeding invertebrates, but there are different mechanisms among the varying species. Some, such as Trypanosoma equiperdum, are spread by direct contact. In an invertebrate host they are generally found in the intestine, but normally occupy the bloodstream or an intracellular environment in the mammalian host. 5 It will be appreciated that references herein to trypanosomal include both Trypanosoma species and Leishmania species of bacteria. Examples of Trypanosoma species include: T. ambystomae, T. antiquus, T. avium, T. boissoni, T. brucei, T. brucei gambiense, T. brucei rhodesiense, T. cruzi, T. congolense, T. 10 equinum, T. equiperdum, T. evansi, T. everetti, T. hosei, T. irwini, T. lewisi, T. melophagium, T. paddae, T. parroti, T. percae, T. rangeli, T. rotatorium, T. rugosae, T. sergenti, T. simiae, T. sinipercae, T. suis, T. theileri, T. triglae, T. tungarae and T. vivax. In one embodiment, the trypanosomal vaccine is a T. congolense, T. brucei, T. brucei 15 gambiense, T. brucei rhodesiense, T. cruzi or T. evansi, vaccine. In a further embodiment, the trypanosomal vaccine is a T. congolense vaccine. Examples of FLA1 binding proteins from T. brucei, T. brucei gambiense, T. cruzi or T. evansi include the following: Trypanosoma brucei Tb427.05.4570 >Tb427.05.4570 | Trypanosoma brucei Lister strain 427 | hypothetical protein, conserved | protein | length=818 MCFIFGVEMSNLAKRPMSLRKLPQLFLLIMIGIAFVAVECIGTPVKLPRRVDTVAGQFGV EGETNGYPNTTRLTEPYALCRGRTNDEILVGSSNSFRNYSRKTKETGXYLRYNVGDSVIS GSSTINKPRSCVRRGSGNHTIIYFVDDQKDIKYIVGDDVSSFSVPTXGSLNAVAVHEGSL YVTDQNNKSVWKCGLGGAGKPQSCEEKKFTSVTLDAKPEGIAVTSKGIFVTARDSSNKGA LLWLDMNGSNRKGNVSGGFVDVFSTESGMLYAATEKELYTVTATDTSLSVTLFAGKNTSS CYFPTNGEDIVLCDNSRLLVIEEYEMYVTSRAKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNXTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLVYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAADATARGKANV TLNTSGVKANDTGVGPNTTNTAGGANTTANVATNGTANVIVNPSTNATPTGTSNASVTNT TERAVPVVAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVD IIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAWGSLIAACLVVLAVVLTSKRRRLA AWAPPRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 5) Tb427.05.4580 >Tb427.05.4580 | Trypanosoma brucei Lister strain 427 | hypothetical protein, conserved | protein | length=818 MCFIFGVEMSNLAKRPMSLRKLPQLFLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQFGF DGTTDGSSNVSMLSSPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTFLRGGPTGGLVS ADAKISKPRSCVRRGSGNHTIIYFVDDQNGLKYINDNEIQHVTVGDGLSLTSVAIYEKDL YVTDQNNKSVWRCNVGGAGKPQNCEEKKFTGLTFTAKPEGIAVTSKGIFVAARDSSNKGA LLWLDMNGGGSKGNVSGGFVDVFSTESGMLYAATEKELYTVTATDSXFSVTLFAGKNTSS CYSHANGEDIVLCDNSRLLVIEEYEMYVTSXEKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNXTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLIYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAAAATARGKANV TLNTSGVKANDTGVGPNTTNTAGGANTTANVVANGTANVIVNPSTNATPTGTSNASVTNT TERAVPVVAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVD IIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAVVGSLIAACLWLAWLTSKRRRLA AWAPPRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 6) Tb427.08.4050 >Tb427.08.4050 | Trypanosoma brucei Lister strain 427 | hypothetical protein, conserved | protein | length=750 MPLWKQTNCEVETMNVREWGTVHLGYVSQMLLLVATVXTIVVRSGAAPIELKRHVTTVA GKYGHIGDKDGFPGMSELSSPHAMCRGRNSDEILLGTVDRFRAFSRKNRETTTITAWETD EDQXSGSRSVKVDKPRACVQWTVGGSTFVYFVESMGEVKYFKDSGVFSHDVVRNGSLTGV ALYGNHLYLTEQNTNTVWTCEVGSDGDPIACHSHVALSAXCSIYGPIGIAATQQGIFVVA RGPAKQGTICWFDLQGHKIAEVDGEYVDITSTRSGDLLAATQNELHRVSTDGNKLTTKRF AGGSTNSCLPNTEGDDTLLCEITRLLWTEYEMYVTSEKKSVLRSVTLPPVYVQGXFPGR PLPVGYPDKDIMEWIVGNLTEDINTALGTTESIVASSSVHVDSTTWLTNFTAGVQQPDFD DEKTEQALHKSNYEHTKEAADEYYNLTDEQVYMDSTMVPYCNRLSLDALRRKLAKEAGEV LNFTLIYADMPLKAESSDAGNITTVKLLMPASFNNTVTHDLLSDANLTETAHSFIKYLRS SDTHVDVTFSNPPFNFSSLTPDEEQEVRWYIHDEVMNQIKKCEERSTGRSMARREEVGDY SRTTIATALDSNVTGVCQSTITNRTVSLFYQPPYVEMSLYEVFIPGNYTFDVSECVGEID WQDLNDHLNNDTVRPTTEKAPKCGRVCLIIIAWCALIVAVLIVLAWFTSKRRRLAAW APARPKFVSTLDEDEQDYASAYGNKERVEQ (SEQ ID NO: 7) Tb427.08.4100 >Tb427.08.4100 | Trypanosoma brucei Lister strain 427 | hypothetical protein, conserved | protein | length=750 MPLWKQTNCEVETMNVREWGTVHLGYVSQMLLLVATVXTIVVRSGAAPIELKRHVTTVA GKYGHIGDKDGFPGMSELSSPHAMCRGRNSDEILLGTVDRFRAFSRKNRETTTITAWETD EDQXSGSRSVKVDKPRACVQWTVGGSTFVYFVESMGEVKYFKDSGVFSHDWRNGSLTGV ALYGNHLYLTEQNTNTVWTCEVGSDGDPIACHSHVALSAXCSIYGPIGIAATQQGIFVVA RGPAKQGTICWFDLQGHKIAEVDGEYVDITSTRSGDLLAATQNELHRVSTDGNKLTTKRF AGGSTNSCLPNTEGDDTLLCEITRLLVVTEYEMYVTSEKKSVLRSVTLPPVYVQGXFPGR PLPVGYPDKDIMEWIVGNLTEDINTALGTTESIVASSSVHVDSTTWLTNFTAGVQQPDFD DEKTEQALHKSNYEHTKEAADEYYNLTDEQVYMDSTMVPYCNRLSLDALRRKLAKEAGEV LNFTLIYADMPLKAESSDAGNITTVKLLMPASFNNTVTHDLLSDANLTETAHSFIKYLRS SDTHVDVTFSNPPFNFSSLTPDEEQEVRWYIHDEVMNQIKKCEERSTGRSMARREEVGDY SRTTIATALDSNVTGVCQSTITNRTVSLFYQPPYVEMSLYEVFIPGNYTFDVSECVGEID WQDLNDHLNNDTVRPTTEKAPKCGRVCLIIIAVVCALIVAVLIVLAVVFTSKRRRLAAW APARPKFVSTLDEDEQDYASAYGNKERVEQ (SEQ ID NO: 8) Tb427_050053100 >Tb427_050053100 | Trypanosoma brucei Lister strain 427 2018 | hypothetical protein, conserved | protein | length=818 MCFIFGVEMSNLAKRPMSLRKLPQLFLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQFGV EGETNGYPNTTRLTEPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTYLRYNVGDSVIS GSSTINKPRSCVRRGSGNHTIIYFVDDQKDIKYIVGDDVSSFSVPTRGSLNAVAVHEGSL YVTDQNNKSVWKCGLGGAGKPQSCEEKKFTSVTLDAKPEGIAVTSKGIFVAARDSSNKGA LLWLDMNGSNRKGNVSGGFVDVFSTESGMLYAATEKELYTVTATDSAFSVTLFAGKNTSQ CYFPTNGEDIVLCDNSRLLVIEEYEMYVTSKEKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNFTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLIYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAAAATARGKANV TLNTSGVKANDTGVGPNTTNTAGGANTTANVVANGTANVIVNPSTNATPTGTSNASVTNT TERAVPVVAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVD IIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAVVGSLIAACLWLAWLTSKRRRUK AWAPPRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 9) Tb427_050053300 >Tb427_050053300 | Trypanosoma brucei Lister strain 427 2018 | hypothetical protein, conserved | protein | length=818 MCFIFGVEMSNLAKRPMSLRKLPQLFLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQFGV EGETNGYPNTTRLTEPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTFLRGGPTGGLVS ADAKISKPRSCVRRGSGNHTIIYFVDDQNGLKYINDNEIQHVTVGDGLSLTSVAIYEKDL YVTDQNNKSVWRCNVGGAGKPQNCEEKKFTGLTFTAKPEGIAVTSKGIFVAARDSSNKGA LLWLDMNGSNRKGNVSGGFVDVFSTESGMLYAATEKELYTVTATDSAFSVTLFAGKNTSS CYSHANGEDIVLCDNSRLLVIEEYEMYVTSMEKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNFTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLIYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAAAVTARGKANV TLNTSGVKANDTGVGPNTTNTAGGANTTANVVANGTANVIVNPSTNATPTGTSNASATNT TERAVPVVAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVD IIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAVVGSLIAACLWLAWLTSKRRRLA AWAPPRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 10) Tb427_050053500 >Tb427_050053500 | Trypanosoma brucei Lister strain 427 2018 | hypothetical protein, conserved | protein | length=810 MCFIFGVEMSNU\KRPMSLRKLPQLFLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQFGV EGETNGYPNTTRLTEPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTFLRGGPTGGLVS ADAKISKPRSCVRRGSGNHTIIYFVDDQNGLKYINDNEIQHVTVGDGLSLTSVAIYEKDL YVTDQNNKSVWRCNVGGAGKPQNCEEKKFTGLTFTAKPEGIAVTSKGIFVAARDSSNKGA LLWLDMNGSNRKGNVSGGFVDVFSTESGMLYAATEKELYTVTATDSAFSVTLFAGKNTSS CYSHANGEDIVLCDNSRLLVIEEYEMYVTSKEKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNYTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLIYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAADATARGKANV TLNTSGVKANDTGVGPNTTNTAGGANTTANVATNGTANVIVNPSTNASVTNTTERAVPW APTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVDIIDWRDLD EMLNNRTDEVVEKSLSWCGHGCIIAFAVVGSLIAACLVVLAWLTSKRRRLAAVVAPPRP KFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 11) Tb427_080045300 >Tb427_080045300 | Trypanosoma brucei Lister strain 427 2018 | hypothetical protein, conserved | protein | length=750 MPLWKQTNCEVETMNVREWGTVHLGYVSQMLLLVATVATIWRSGAAPIELKRHVTTVA GKYGHIGDKDGFPGMSELSSPHAMCRGRNSDEILLGTVDRFRAFSRKNRETTTITAWETD EDQKSGSRSVKVDKPRACVQWTVGGSTFVYFVESMGEVKYFKDSGVFSHDVVRNGSLTGV ALYGNHLYLTEQNTNTVWTCEVGSDGDPIACHSHVALSANCSIYGPIGIAATQQGIFVVA RGPAKQGTICWFDLQGHKIAEVDGEYVDITSTRSGDLLAATQNELHRVSTDGNKLTTKRF AGGSTNSCLPNTEGDDTLLCEITRLLVVTEYEMYVTSEKKSVLRSVTLPPVYVQGLFPGR PLPVGYPDKDIMEWIVGNLTEDINTALGTTESIVASSSVHVDSTTWLTNFTAGVQQPDFD DEKTEQALHKSNYEHTKEAADEYYNLTDEQVYMDSTMVPYCNRLSLDALRRKLAKEAGEV LNFTLIYADMPLKAESSDAENITTVKLLMPASFNNTVTHDLLSDANLTETAHSFIKYLRS SDTHVDVTFSNPPFNFSSLTPDEEQEVRWYIHDEVMNQIKKCEERSTGRSMARREEVGDH SRTTIATALDSNVTGVCQSTITNRTVSLFYQPPYVEMSLYEVFIPGNYTFDVSECVGEID WQDLNDHLNNDTVRPTTEKAPKCGRVCLIIIAWCALIVAVLIVLAWFTSKRRRLAAW APARPKFVSTLDEDEQDYASAYGNKERVEQ (SEQ ID NO: 12) Tb427_080045800 >Tb427_080045800 | Trypanosoma brucei Lister strain 427 2018 | hypothetical protein, conserved | protein | length=750 MPLWKQTNCEVETMNVREWGTVHLGYVSQMLLLVATVETIWRSGAAPIELKRHVTTVA GKYGHIGDKDGFPGMSELSSPHAMCRGRNSDEILLGTVDRFRAFSRKNRETTTITAWETD EDQNSGSRSVKVDKPRACVQWTVGDSTFVYFVESMGEVKYFKDSGVFSHDWRNGSLTGV ALYGNHLYLTEQNTNTVWTCEVGSDGDPIACHSHVALSAKCSIYGPIGIAATQQGIFVVA RGPAKQGTICWFDLQGHKIAEVDGEYVDITSTRSGDLLAATQNELHRVSTDGNKLTTKRF AGGSTNSCLPNTEGDDTLLCEITRLLVVTEYEMYVTSEKKSVLRSVTLPPVYVQGVFPGR PLPVGYPDKDIMEWIVGNLTEDINTALGTTESIVASSSVHVDSTTWLTNFTAGVQQPDFD DEKTEQALHKSNYEHTKEAADEYYNLTDEQVYMDSTMVPYCNRLSLDALRRKLAKEAGEV LNFTLIYADMPLKAESSDAGNITTVKLLMPASFNNTVTHDLLSDANLTETAHSFIKYLRS SDTHVDVTFSNPPFNFSSLTPDEEQEVRWYIHDEVMNQIKKCEERSTGRSMARREEVGDY SRTTIATALDSNVTGVCQSTITNRTVSLFYQPPYVEMSLYEVFIPGNYTFDVSECVGEID WQDLNDHLNNDTVRPTTEKAPKCGRVCLIIIAWCALIVAVLIVLAWFTSKRRRLAAW APARPKFVSTLDEDEQDYASAYGNKERVEQ (SEQ ID NO: 13) Tb927.5.4570 >Tb927.5.4570 | Trypanosoma brucei brucei TREU927 | Flagellum adhesion protein 3 | protein | length=818 MCFIFGVEMSNLAKRPMSLRKLPQLLLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQFGV EGETNGYPNTTRLTEPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTYLRYNVGDSVIS GSSTINKPRSCVRRGSGNHTIIYFVDDQKDIKYIVGDDVSSFSVPTSGSLNAVAVHEGTL YVTDQNNKSVWKCGLGGAGKPQSCEEKKFTSVTLDAKPEGIAVTSKGIFVTARDSSNKGA LLWLDMSGGNRKGNVSGGFVDVFSTESGVLYAATEKELYTVTATDTSLSVTSFAGKNTSQ CYFPTNGEDIVLCDNSRLLVIEEYEMYVTSKAKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNFTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLVYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAADATARGKANV TLNTSGVKANDTGVGPNTTNTAGGANTTANVAANGTANVIVNPSTNATPTGTTNASVTNT TERAVPVVAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVD IIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAVVGSLIAACLWLAWLTSKRRRLA AWAPPRPKFVSTVEDDDEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 14) Tb927.5.4580 >Tb927.5.4580 | Trypanosoma brucei brucei TREU927 | Flagellum adhesion protein 3 | protein | length=818 MCFIFGVEMSNLAKRPMSLRKLPQLLLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQFGF DGTTDGSSNVSMLSSPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTFLRGGPTGGLVS ADAKISKPRSCVRRGSGNHTIIYFVDDQNGLKYINDNEIQHVTVGNGLSLTSVAIYEKDL YVTDQNNKSVWRCNVGGAGKPQNCEEKKFTGLTFTAKPEGIAVTSKGIFVAARDSSNKGA LLWLDMNGGGSKGNVSGGFVDVFSTESGMLYAATEKELYTVTATGSAFSVTSFAGKNTSS CYSHANGEDIVLCDNSRLLVIEEYEMYVTSKEKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNFTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLIYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAAAATARGKANV TLNTSGVKANDTGVGPNTTNTAGGANTTANWANGTANVIVNPSTNATPTGTTNASVTNT TERAVPWAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVD IIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAVVGSLIAACLWLAWLTSKRRRLA AWAPPRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 15) Tb927.8.4050 >Tb927.8.4050 | Trypanosoma brucei brucei TREU927 | FLA1 -binding protein | protein | length=750 M PLWKQTNCEVETM NVREVVGTVH LGYVSQMLLLVATVATIWRSGAAPIELKRHVTTVA GKYGHIGDKDGFPGMSELSSPHAMCRGRNSDEILLGTVDRFRAFSRKNRETTTITAWETD EDQKSGSRSVKVDKPRACVQWTVGGSTFVYFVESMGEVKYFKDSGVFSHDWRNGSLTGV ALYGNHLYLTEQNTNTVWTCEVGSDGDPIACHSHVALSANCSIYGPIGIAATQQGIFVVA RGPAKQGTICWFDLQGHKIAEVDGEYVDITSTRSGDLLAATQNELHRVSTDGNKLTTKRF AGGSTNSCLPNTEGDDTLLCEITRLLVVTEYEMYVTSEKKSVLRSVTLPPVYVQGLFPGR PLPVGYPDKDIMEWIVGNLTEDINTALGTTESIVASSSVHVDSTTWLTNFTAGVQQPDFD DEKTEQALHESNYEHTKEAADEYYNLTDEQVYMDSTMVPYCNRLSLDALRRKLAKEAGEV LNFTLIYADMPLKAESSDAENITTVKLLMPASFNNTVTHDLLSDANLTETAHSFIKYLRS SDTHVDVTFSNPPFNFSSLTPDEEQEVRWYIHDEVMNQIKKCEERSTGRSMARREEVGDH SRTTIATALDSNVTGVCQSTITNRTVSLFYQPPYVEMSLYEVFIPGNYTFDVSECVGEID WQDLNDHLNNDTVRPTTEKAPKCGRVCLIIIAWCALIVAVLIVLAWFTSKRRRLAAW APARPKFVSTLDEDEQDYASAYGNKERVEQ (SEQ ID NO: 16) Tb927.8.4100 >Tb927.8.4100 | Trypanosoma brucei brucei TREU927 | FLAd-binding protein | protein | length=750 MPLWKQTNCEVETMNVREWGTVHLGYVSQMLLLVATVATIVVRSGAAPIELKRHVTTVA GKYGHIGDKDGFPGMSELSSPHAMCRGRNSDEILLGTVDRFRAFSRKNRETTTITAWETD EDQKSGSRSVKVDKPRACVQWTVGGSTFVYFVESMGEVKYFKDSGVFSHDWRNGSLTGV ALYGNHLYLTEQNTNTVWTCEVGSDGDPIACHSHVALSANCSIYGPIGIAATQQGIFVVA RGPAKQGTICWFDLQGHKIAEVDGEYVDITSTRSGDLLAATQNELHRVSTDGNKLTTKRF AGGSTNSCLPNTEGDDTLLCEITRLLVVTEYEMYVTSEKKSVLRSVTLPPVYVQGLFPGR PLPVGYPDKDIMEWIVGNLTEDINTALGTTESIVASSSVHVDSTTWLTNFTAGVQQPDFD DEKTEQALHESNYEHTKEAADEYYNLTDEQVYMDSTMVPYCNRLSLDALRRKLAKEAGEV LNFTLIYADMPLKAESSDAENITTVKLLMPASFNNTVTHDLLSDANLTETAHSFIKYLRS SDTHVDVTFSNPPFNFSSLTPDEEQEVRWYIHDEVMNQIKKCEERSTGRSMARREEVGDH SRTTIATALDSNVTGVCQSTITNRTVSLFYQPPYVEMSLYEVFIPGNYTFDVSECVGEID WQDLNDHLNNDTVRPTTEKAPKCGRVCLIIIAVVCALIVAVLIVLAWFTSKRRRLAAW APARPKFVSTLDEDEQDYASAYGNKERVEQ (SEQ ID NO: 17) Tb05.5K5.210 >Tb05.5K5.210 | Trypanosoma brucei brucei TREU927 | hypothetical protein | protein | length=818 MCFIFGVEMSNLAKRPMSLRKLPQLLLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQFGV EGETNGYPNTTRLTEPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTYLRYNVGDSVIS GSSTINKPRSCVRRGSGNHTIIYFVDDQKDIKYIVGDDVSSFSVPTSGSLNAVAVHEGSL YVTDQNNKSVWKCGLGGAGKPQSCEEKKFTSVTLDAKPEGIAVTSKGIFVTARDSSNKGA LLWLDMSGSNRKGNVSGGFVDVFSTESGVLYAATEKELYTVTATDTSLSVTLFAGKNTSQ CYFSTNGEDIVLCDNSRLLVIEEYEMYVTSKEKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPNTWETNYTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLIYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAADATARGKANV TLNTSGVKANDTGVGPNTTNTAGGADTTANVAANGTANVIVNPSTNATPTGTTNASVTNT TERAVPWAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVD IIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAVVGSLIAACLWLAWLTSKRRRLA AWAPPRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 18) Tb05.5K5.220 >Tb05.5K5.220 | Trypanosoma brucei brucei TREU927 | hypothetical protein | protein | length=818 MCFIFGVEMSNLAKRPMSLRKLPQLLLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQFGF DGTTDGSSNVSMLSSPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTFLRGGPTGGLVS ADAKISKPRSCVRRGSGNHTIIYFVDDQNGLKYINDNEIQHVTVGNGLSLTSVAIYEKDL YVTDQNNKSVWRCNVGGAGKPQNCEEKKFTGLTFTAKPEGIAVTSKGIFVAARDSSNKGA LLWLDMNGGGSKGNVSGGFVDVFSTESGMLYAATEKELYTVTATDSAFSVTSFAGKNTSS CYSHANGEDIVLCDNSRLLVIEEYEMYVTSKEKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNFTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLIYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAAAATARGKANV TLNTSGVKANDTGVGPNTTNTAGGANTTANVAANGTANVIVNPSTNATPTGTTNASVTNT TERAVPVVAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVD IIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAWGSLIAACLWLAWLTSKRRRLA AWAPPRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 19) Tb11.v5.0364 >Tb11.v5.0364 | Trypanosoma brucei brucei TREU927 | hypothetical protein, conserved | protein | length=820 LAMCFIFGVEMSNLAKRPMSLRKLPQLLLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQF GFDGTTDGSSNVSMLSSPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTFLRGGPTGGL VSADAKISKPRSCVRRGSGNHTIIYFVDDQNGLKYINDNEIQHVTVGNGLSLTSVAIYEK DLYVTDQNNKSVWRCNVGGAGKPQNCEEKKFTGLTFTAKPEGIAVTSKGIFVAARDSSNK GALLWLDMNGGGSKGNVSGGFVDVFSTESGMLYAATEKELYTVTATGSAFSVTSFAGKNT SSCYSHANGEDIVLCDNSRLLVIEEYEMYVTSKEKHTMRALTLPPVNLTAIFRGRPAPVG YPNTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNFTVFVQQTRFDNTTEE KLRSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLI YADKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVD ITFPDPPFNFSAWPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAADATARGKA NVTLNTSGVKANDTGVGPNTTNTAGGANTTANVAANGTANVIVNPSTNATPTGTTNASVT NTTERAVPVVAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWC VDIIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAVVGSLIAACLWLAVVLTSKRRR LAAWAPPRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 20) Trypanosoma brucei gambiense Tbg972.5.6160 >Tbg972.5.6160 | Trypanosoma brucei gambiense DAL972 | hypothetical protein, conserved (fragment) | protein | length=573 MSGSNRKGNVSGGFVDVFSTESGMLYAATEKELYTVTATDTSLSVTLFAGKNTSSCYSHA NGEDIVLCDNSRLLVIEEYEMYVTSKEKHTMRALTLPPVNLTAIFRGRPAPVGYPNTTIM EQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNYTVFVQQTRFDNTTEEKLRSLTY TQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLIYADKPIT FGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDITFPDPP FNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAADATARGKANVTLNTS GVKANDTGVGPNTTNTAGGANTTANVATNGTANVIVNPSTNATPTGTSNASATNTTERAV PWAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVDIIDWR DLDEMLNNRTDEVVEKSLSWCGHGCIIAFAVVGSLIAACLWLAVVLTSKRRRLAAWAP PRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 21) Tbg972.5.6180 >Tbg972.5.6180 | Trypanosoma brucei gambiense DAL972 | hypothetical protein, conserved | protein | length=818 MCFIFGVEMSNLAKRPMSLRKLPQLFLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQFGF DGTTDGSSNVSMLSSPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTFLRGGPTGGLVS ADAKISKPRSCVRRGSGNHTIIYFVDDQNGLKYINDNEIQHVTVGNGLSLNAVAIHEKDL YVTDQNNKSVWRCNVGGAGKPQNCEEKKFTGVTFTAKPEGIAVTSKGIFVTARDSSNKGA LLWLDMNGGGRKGNVSGGFVDVFSTESGVLYAATEKELYTVTATDTSLSVTLFAGKNTSQ CYFPTNGEDIVLCDNSRLLVIEEYEMYVTSKAKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNYTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRAU\REAGRALNFSLIYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAADATARGKANV TLNTSGVKANDTGVGPNTTNTAGGANTTANVATNGTANVIVNPSTNATPTGTSNASATNT TERAVPVVAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVD IIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAVVGSLIAACLWU\WLTSKRRRU\ AWAPPRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 22) Tbg972.8.3750 >Tbg972.8.3750 | Trypanosoma brucei gambiense DAL972 | FLA1 -binding protein | protein | length=750 MPLWKQTNCEVETMNVREWGTVHLGYVSQMLLLVATVETIVVRSGAAPIELKRHVTTVA GKYGHIGDKDGFPGMSELSSPHAMCRGRNSDEILLGTVDRFRAFSRKNRETTTITAWETD EDQNSGSRSVKVDKPRACVQWTVGDSTFVYFVESMGEVKYFKDSGVFSHDVVRNGSLTGV ALYGNHLYLTEQNTNTVWTCEVGSDGDPIACHSHVALSAKCSIYGPIGIAATQQGIFVVA RGPAKQGTICWFDLQGHKIAEVDGEYVDITSTRSGDLLAATQNELHRVSTDGNKLTTKRF AGGSTNSCLPNTEGDDTLLCEITRLLVVTEYEMYVTSEKKSVLRSVTLPPVYVQGVFPGR PLPVGYPDKDIMEWIVGNLTEDINTALGTTESIVASSSVHVDSTTWLTNFTAGVQQPDFD DEKTEQALHKSNYEHTKEAADEYYNLTDEQVYMDSTMVPYCNRLSLDALRRKLAKEAGEV LNFTLIYADMPLKAESSDAGNITTVKLLMPASFNNTVTHDLLSDANLTETAHSFIKYLRS SDTHVDVTFSNPPFNFSSLTPDEEQEVRWYIHDEVMNQIKKCEERSTGRSMARREEVGDY SRTTIATALDSNVTGVCQSTITNRTVSLFYQPPYVEMSLYEVFIPGNYTFDVSECVGEID WQDLNDHLNNDTVRPTTEKAPKCGRVCLIIIAWCALIVAVLIVLAVVFTSKRRRLAAW APARPKFVSTLDEDEQDYASAYGNKERVEQ (SEQ ID NO: 23) Tbg972.8.3800 >Tbg972.8.3800 | Trypanosoma brucei gambiense DAL972 | FLA1-binding protein (fragment) | protein | length=600 FVESIGEVKYFRDSGVFSHDWRNGSLTGVALYGNHLYLTEQNTNTVWTCEVGSDGDPIA CHSHVALSAKCSIYGPIGIAATQQGIFWARGPAKQGTICWFDLQGHKIAEVDGEYVDIT STRSGDLLAATQNELHRVSTDGNKLTTKRFAGGSTNSCLPNTEGDDTLLCEITRLLVVTE YEMYVTSEKKSVLRSVTLPPVYVQGVFPGRPLPVGYPDKDIMEWIVGNLTEDINTALGTT ESIVASSSVHVDSTTWLTNFTAGVQQPDFDDEKTEQALHKSNYEHTKEAADEYYNLTDEQ VYMDSTMVPYCNRLSLDALRRKLAKEAGEVLNFTLIYADMPLKAESSDAGNITTVKLLMP ASFNNTVTHDLLSDANLTETAHSFIKYLRSSDTHVDVTFSNPPFNFSSLTPDEEQEVRWY IHDEVMNQIKKCEERSTGRSMARREEVGDYSRTTIATALDSNVTGVCQSTITNRTVSLFY QPPYVEMSLYEVFIPGNYTFDVSECVGEIDWQDLNDHLNNDTVRPTTEKAPKCGRVCLII IAWCALIVAVLIVLAVVFTSKRRRLAAVVAPARPKFVSTLDEDEQDYASAYGNKERVEQ (SEQ ID NO: 24) Trypanosoma cruzi TcBrA4_0018970 >TcBrA4_0018970 | Trypanosoma cruzi Brazil A4 | hypothetical protein | protein | MELPPPPLPIGYPDDNEVMKKIIQLMNEELNEHLKTNGTYVSQENMYVDANTWATKFAVM VQQHDFENATTPGEVLTTHFAQTKQFVKDYYDRVDEVLYMDTSIMPFCNDTMLNAVMHRL VSWREVSVFRLFTPTRQRLGRNLILKTSPQ (SEQ ID NO: 25) length=151 >TcBrA4_0018980 | Trypanosoma cruzi Brazil A4 | hypothetical protein, conserved | protein length=218 TcBrA4_0018980 MDADMDAALLQILRELYGPENVVTLVFPMPEYDFSKLTDEQLVEIRWFILDMVRARLEEC AVLSAGSVDASVSRHSGVCEAVITNRTETVISHPPFNIQSEYEVFVPSRYNFNASLCLDG IDWAVLEEVIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIAVVWLTSKRRRLAA VVAPVHPKFKSTLDEDEEEIETTNPLELKEEQRARDMY (SEQ ID NO: 26) TcBrA4_0019750 >TcBrA4_0019750 | Trypanosoma cruzi Brazil A4 | hypothetical protein, conserved | protein | length=712 MFRFQSLLFALFTGLLFSFTSSVVVAMPLRYMVETVSGITGSIGHVNGGPGASLLTRPSA ICQGRNEDELLFGTQGYFRNFSRSTKMTGILIGDGTAQILDGTWSQARIDGPRGCVRGIF NQKMIVYFVEGQSSLRYFTSNYVHTVIISINLSFTDVKLYEGKLYITEQTKDEVWVCDID ADGAPVSCALKTGFKCDYGKYHGITVTKLGVFVVGESAAGICHFDMNGNKISVLGGNYID VFSLPSDELYIMSYTELLHLRVTGSAMAVEKFAGRADATCPPLIDGYDFTLCKNLRLFVI EQSEMYLATTLNTVRSVTLPPAIVWMELPPPPLPIGYPDDNEVMKKIIQLMNEELNEHLK TNGTYVSQENMYVDANTWATKFAVMVQQHDFENATTPGEVLTTHFAQTKQFVKDYYDRVD EVLYMDTSIMPFCNDTMLNAVMHRLVSWREVLGFPLIYANPPEARKEFNFENITTMKLL MPASFNNDTTRDALMDADMDAALLQILRELYGPENVVTLVFPMPEYDFSKLTDEQLVEIR WFILDMVRARLEECAVLSAGSVDASVSRHSGVCEAVITNRTETVISHPPFNIQSEYEVFV PSRYNFNASLCLDGIDWAVLEEVIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIA VWVLTSKRRRLAAVVAPVHPKFKSTLDEDEEEIETTNPLELKEEQRARDMY (SEQ ID NO: 27) TcCLB.503571.19 >TcCLB.503571.19 | Trypanosoma cruzi CL Brener Esmeraldo-like | FLA1-binding protein | protein | length=708 MSRFQRLLFALFAGFLFSFTASVVVAMPLRYMVETVSGITGSIGHVNGGPGTSLLTRPSA ICQGRNEDELLFGTQGYFRNFSRSTKMTGILLGDGTVQILDGTWSQARIDGPRGCVRGIF NQKMIVYFVEGQSSLRYFTSNYVHTVTISINLSFTDVKLYEGKLYITEQTKDEVWGCDID ADGAPVSCALKTGFKCDYGKYHGITVTKLGVFWGESAAGICHFDMHGNKISVLGGNYID VFSLPSDELYIMSYTELLHLRVIGSAMWEKFAGRSDATCPPLIDGYDFTLCKNLRLFVI EQSEMYLATTLNTVRSVTLPPAIVWIELPPPPLPIGYPNDNEVMKKIIQLMNEELNKHLG TNGTYVSQETMHVDANTWATKFAVMVQQQDFENATTPGEVLTTHFARTKQFVKDYYDRVN EVLYMDTSIMPFCNDTMLNAVMHRLVTWREVLSFPLIYANPPEVRKEFDFENITTMKLL MPASFNNDTTREALMDADMDAALLQILRELYGPEHWTLVFPMPQYDFSKLTDEQLVEVR WFILDLVRARLEECAVLSVDGVGASVSSHSSVCEAVITNRTETVVSHPPFNIQSEYEVFV PSRYKFNASLCLDGIDWTVLEELIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIA VMWLTSKRRRLAAVVAPVHPKFKSTLDEDEEEMETTNPLEVKDEQRA (SEQ ID NO: 28) TcC LB.509561.9 >TcCLB.509561.9 | Trypanosoma cruzi CL Brener Non-Esmeraldo-like | FLA1 -binding protein | protein | length=366 MFWFQSLLFALFAGLLFSFTSSVWAMPLRYMVETVSGITGSIGHANGGPGTSLLTRPSA ICQGRNEDELLFGTQGYFRNFSRSTKMTGILIGDGTAQILDGTWSQARIDGPRGCVRGIF SQKMIVYFVEGQSSLRYFTSDYVHTVMISINLFFTDVKLYEGKLYMTEQTKDEVWGCDID ADGAPVSCALKTGFKCDYGKYHGITVTKQGVFWGESAAGICHFDMHGNKLSVLGGNYID VFSLPSDELYIMSYTELFHLRVIGSAMWEKFAGRADATCPPLIDGYDFTLCKNLRLFVI DQSEMYLATTLNTVRSVTLPPAIVWMELPPPPLPIGYPDEYEVMKRIIQLMNEELNEHLR TNGTYV (SEQ ID NO: 29) TCDM_03241 >TCDM_03241 | Trypanosoma cruzi Dm28c 2014 | hypothetical protein | protein | length=712 MFRFQSLLFALFTGLLFSFTSSVVVAMPLRYMVETVSGITGSIGHVNGGPGASLLTRPSA ICKGRNEDELLFGTQGYFRNFSRSTKMTGILIGDGTAQILDGTWSQARIDGPRGCVRGIF NQKMIVYFVEGQSSLRYFTSNYVHTVIISINLSFTDVKLYEGKLYITEQTKDEVWVCDID ADGAPVSCALKTGFKCDYGKYHGITVTKLGVFVVGESAAGICHFDMNGNKISVLGGNYID VFSLPSDELYIMSYTELLHLRVTGSAMAVEKFAGRADATCPPLIDGYDFTLCKNLRLFVI EQSEMYLATTLNTVRSVTLPPAIVWMELPPPPLPIGYPDDNEVMKKIIQLMNEELNEHLK TNGTYVSQENMYVDANTWATKFAVMVQQHDFENATTPGEVLTTHFAQTKQFVKDYYDRVD EVLYMDTSIMPFCNDTMLNAVMHRLVSWREVLGFPLIYANPPEARKEFNFENITTMKLL MPASFNNDTTRDALMDADMDAALLQILWELYGPENWTLVFPMPEYDFSKLTDEQLVEIR WFILDMVRARLEECAVLSAGSVDASVSRHSGVCEAVITNRTETVISHPPFNIQSEYEVFV PSRYNFNASLCLDGIDWAVLEEVIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIA VWVLTSKRRRLAAVVAPVHPKFKSTLDEDEEEIETTNPLELKEEQRARDMY (SEQ ID NO: 30) BCY84_05332 >BCY84_05332 | Trypanosoma cruzi Dm28c 2017 | hypothetical protein | protein | MFRFQSLLFALFTGLLFSFTSSVVVAMPLRYMVETVSGITGSIGHVNGGPGASLLTRPSA ICKGRNEDELLFGTQGYFRNFSRSTKMTGILIGDGTAQILDGTWSQARIDGPRGCVRGIF NQKMIVYFVEGQSSLRYFTSNYVHTVIISINLSFTDVKLYEGKLYITEQTKDEVWVCDID ADGAPVSCALKTGFKCDYGKYHGITVTKLGVFVVGESAAGICHFDMNGNKISVLGGNYID VFSLPSDELYIMSYTELLHLRVTGSAMAVEKFAGRADATCPPLIDGYDFTLCKNLRLFVI EQSEMYLATTLNTVRSVTLPPAIVWMELPPPPLPIGYPDDNEVMKKIIQLMNEELNEHLK TNGTYVSQENMYVDANTWATKFAVMVQQHDFENATTPGEVLTTHFAQTKQFVKDYYDRVD EVLYMDTSIMPFCNDTMLNAVMHRLVSVVREVLGFPLIYANPPEARKEFNFENITTMKLL MPASFNNDTTRDALMDADMDAALLQILWELYGPENWTLVFPMPEYDFSKLTDEQLVEIR WFILDMVRARLEECAVLSAGSVDASVSRHSGVCEAVITNRTETVISHPPFNIQSEYEVFV PSRYNFNASLCLDGIDWAVLEEVIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIA VWVLTSKRRRLAAVVAPVHPKFKSTLDEDEEEIETTNPLELKEEQRARDMY (SEQ ID NO: 31) length=712 C4B63_21g106 >C4B63_21g106 | Trypanosoma cruzi Dm28c 2018 | FLA1-binding protein | protein MFRFQSLLFALFTGLLFSFTSSVVVAMPLRYMVETVSGITGSIGHVNGGPGASLLTRPSA ICKGRNEDELLFGTQGYFRNFSRSTKMTGILIGDGTAQILDGTWSQARIDGPRGCVRGIF NQKMIVYFVEGQSSLRYFTSN YVHTVII SI N LSFTDVKLYEG KLYITEQTKDEWWCDID ADGAPVSCALKTGFKCDYGKYHGITVTKLGVFWGESAAGICHFDMNGNKISVLGGNYID VFSLPSDELYIMSYTELLHLRVTGSAMAVEKFAGRADATCPPLIDGYDFTLCKNLRLFVI EQSEMYLATTLNTVRSVTLPPAIVWMELPPPPLPIGYPDDNEVMKKIIQLMNEELNEHLK length=712 TNGTYVSQENMYVDANTWATKFAVMVQQHDFENATTPGEVLTTHFAQTKQFVKDYYDRVD EVLYMDTSIMPFCNDTMLNAVMHRLVSWREVLGFPLIYANPPEARKEFNFENITTMKLL MPASFNNDTTRDALMDADMDAALLQILWELYGPENWTLVFPMPEYDFSKLTDEQLVEIR WFILDMVRARLEECAVLSAGSVDASVSRHSGVCEAVITNRTETVISHPPFNIQSEYEVFV PSRYNFNASLCLDGIDWAVLEEVIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIA VWVLTSKRRRLAAVVAPVHPKFKSTLDEDEEEIETTNPLELKEEQRARDMY (SEQ ID NO: 32) TcSYL. .0095950 >TcSYL_0095950 | Trypanosoma cruzi Sylvio X10 / 1 | unspecified product | protein | MDADMDAALLQILRELYGPENWTLVFPMPEYDFSKLTDEQLVEIRWFILDMVRARLEEC AVLSAGSVDASVSRHSGVCEAVITNRTETVIPHPPFNIQSEYEVFVPSRYNFNASLCLDG IDWAVLEEVIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIAWVVLTSKRRRLAA VVAPVHPKFKSTLDEDEEEIETTNPLELKEEQRARDM (SEQ ID NO: 33) length=217 TcSYL. .0095960 >TcSYL_0095960 | Trypanosoma cruzi Sylvio X10 / 1 | unspecified product | protein | MIVYFVEGQSSLRYFTSNYVHTVIISINLSFTDVKLYEGKLYITEQTKDEVVWCDIDADG APVSCALKTGFKCDYGKYHGITVTKLGVFVVGESAAGICHFDMNGNKISVLGGNYIDVFS LPSDELYIMSYTELLHLRVTGSAMAVEKFAGRADATCPPLIDGYDFTLCKNLRLFVIEQS EMYLATTLNTVRSVTLPPAIVWMELPPPPLPIGYPDDNEVMKKIIQLMNEELNEHLKTNG TYVSQENMYVDDNTWATKFAVMVQQHDFENATTPGEVLTTHFAQTKQFVKDYYDRVDEVL YMDTSIMPFCNDTMLNAVMHRLVSVVREVLVFRLFTPTRQRLGRNLILKTSPQ (SEQ ID NO: 34) length=353 TCSYLVIO_000059 >TCSYLVIO_000059 | Trypanosoma cruzi Sylvio X10 / 1-2012 | hypothetical protein | protein MFRFQSLLFALFTGLLFSFTSSVVVAMPLRYMVETVSGITGSIGHVNGGPGASLLTRPSA ICQGRNEEELLFGTQGYFRNFSRSTKMTGILIGDGTAQILDGTWSQARIDGPRGCVRGIF NQKMIVYFVEGQSSLRYFTSNYVHTVIISINLSFTDVKLYEGKLYITEQTKDEVWVCDID ADGAPVSCALKTGFKCDYGKYHGITVTKLGVFVVGESAAGICHFDMNGNKISVLGGNYID length=711 VFSLPSDELYIMSYTELLHLRVTGSAMAVEKFAGRADATCPPLIDGYDFTLCKNLRLFVI EQSEMYLATTLNTVRSVTLPPAIVWMELPPPPLPIGYPDDNEVMKKIIQLMNEELNEHLK TNGTYVSQENMYVDANTWATKFAVMVQQHDFENATTPGEVLTTHFAQTKQFVKDYYDRVD EVLYMDTSIMPFCNDTMLNAVMHRLVSWREVLGFPLIYANPPEARKEFNFENITTMKLL MPASFNNDTTRDALMDADMDAALLQILRELYGPENVVTLVFPMPEYDFSKLTDEQLVEIR WFILDMVRARLEECAVLSAGSVDASVSRHSGVCEAVITNRTETVIPHPPFNIQSEYEVFV PSRYNFNASLCLDGIDWAVLEEVIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIA VWVLTSKRRRLAAVVAPVHPKFKSTLDEDEEEIETTNPLELKEEQRARDM (SEQ ID NO: 35) C3747_125g76 >C3747_125g76 | Trypanosoma cruzi TCC | FLA1-binding protein | protein | MSRFQRLLFALFAGFLFSFTASVVVAMPLRYMVETVSGITGSIGHVNGGPGTSLLTRPSA ICQGRNEDELLFGTQGYFRNFSRSTKMTGILLGDGTVQILDGTWSQARIDGPRGCVRGIF NQKMIVYFVEGQSSLRYFTSNYVHTVTISINLSFTDVKLYEGKLYITEQTKDEVWGCDID ADGAPVSCALKTGFKCDYGKYHGITVTKLGVFVVGESAAGICHFDMHGNKISVLGGNYID VFSLPSDELYIMSYTELLHLRVIGSAMWEKFAGRSDATCPPLIDGYDFTLCKNLRLFVI EQSEMYLATTLNTVRSVTLPPAIVWIELPPPPLPIGYPNDNEVMKKIIQLMNEELNKHLG TNGTYVSQETMHVDANTWATKFAVMVQQQDFENATTPGEVLTTHFARTKQFVKDYYDRVN EVLYMDTSIMPFCNDTMLNAVMHRLVTWREVLSFPLIYANPPEVRKEFDFENITTMKLL MPASFNNDTTREALMDADMDAALLQILRELYGPEHWTLVFPMPQYDFSKLTDEQLVEVR WFILDLVRARLEECAVLSVDGVGASVSSHSSVCEAVITNRTETVVSHPPFNIQSEYEVFV PSRYKFNASLCLDGIDWTVLEELIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIA VMWLTSKRRRLAAVVAPVHPKFKSTLDEDEEEMETTNPLEVKDEQRARDMY (SEQ ID NO: 36) length=712 C3747_66g107 >C3747_66g107 | Trypanosoma cruzi TCC | FLA1-binding protein | protein | MFWFQSLLFALFAGLLFSFTSSWVAMPLRYMVETVSGITGSIGHANGGPGTSLLTRPSA length=712 ICQGRNEDELLFGTQGYFRNFSRSTKMTGILIGDGTAQILDGTWSQARIDGPRGCVRGIF SQKMIVYFVEGQSSLRYFTSDYVHTVMISINLFFTDVKLYEGKLYMTEQTKDEVWGCDID ADGAPVSCALKTGFKCDYGKYHGITVTKQGVFWGESAAGICHFDMHGNKLSVLGGNYID VFSLPSDELYIMSYTELFHLRVIGSAMWEKFAGRADATCPPLIDGYDFTLCKNLRLFVI DQSEMYLATTLNTVRSVTLPPAIVWMELPPPPLPIGYPDDNEVMKRIIQLMNEELNEHLR TNGTYVSQENMHVDADTWATKFAVMVQQHDFENATTPGEVLTTHFAQTTQFVKDYYDRVD EVLYMDTSIMPFCNDTMLNAVMHRLVSVVREVLGFPLIYANPPEARKELNFENITTMKLL MPASFNNDTTRDALMDADMDAALLQILRELYGPENVVTLVFPMPQYDFSKLTDEQLVEVR WFILDLVRARLEECDVLSASSVDASVSSHSGVCEAVITNRTETVVSHPPFNVQSEYEVFV PLRYKFNASLCLDGIDWAVLEEIIKNYTEENKPRRKSACDRSCIIGLAVLAALVLTALIA VWVLTSKRRRLAAVVAPVHPKFKSTLDEDEEEIETTNPLEVKDEQRARDMY (SEQ ID NO: 37) TcYC6_ .0063920 >TcYC6_0063920 | Trypanosoma cruzi Y C6 | hypothetical protein, conserved | protein MHVDANTWATKFAVMVQQQDFENATTPGEVLTTHFTRTKQFVKDYYDRVNEVLYMDTSIM PFCNDTMLNAVMHRLVSWREVLSFPLIYANPPEVRKEFDFENITTMKLLMPASFNNDTT REALMDADMDAALLQILRELYGPEHWTLVFPMPQYDFSKLTDEQLVEVRWFILDLVRAR LEECAVLSVDGVGASVSSHSSVCEAVITNRTETWSHPPFNIQSEYEVFVPSRYKFNASL CLDGIDWAVLEELIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIAVIVIWLTSKRR RLAAWAPVHPKIKSTLDEDEEEMETTNPLEVKDEQRARDMY (SEQ ID NO: 38) length=342 TcYC6_ .0064040 >TcYC6_0064040 | Trypanosoma cruzi Y C6 | FLA1 -binding protein | protein | MSRFQSLLFALFAGFLFSFTASWVAMPLRYMVETVSGITGSIGHVNGGPGTSLLTRPSA ICQGRNEDELLFGTQGYFRNFSRSTKMTGILLGDGTAQILDGTWSQARIDGPRGCVRGIF NQKMIVYFVEGQSSLRYFTSNYVHTVTISINLSFTDVKLYEGKLYITEQTKDEVWGCDID ADGAPVSCALKTGFKCDYGKYHGITVTKLGVFWGESAAGICHFDMHGNKISVLGGNYID length=712 VFSLPSDELYIMSYTELLHLRVIGSAMVVEKFAGRSDATCPPLTDGYDFTLCKNLRLFVI EQSEMYLATTLNTVRSVTLPPAIVWIELPPPPLPIGYPNDNEVMKKIIQLMNEELNKHLG TNGTYVSQETMHVDANTWATKFAVMVQQQDFENATTPGEVLTTHFTRTKQFVKDYYDRVN EVLYMDTSIMPFCNDTMLNAVMHRLVSWREVLSFPLIYANPPEVRKEFDFENITTMKLL MPASFNNDTTREALMDADMDAALLQILRELYGPEHVVTLVFPMPQYDFSKLTDEQLVEVR WFILDLVRARLEECAVLSVDGVGASVSSHSSVCEAVITNRTETVVSHPPFNIQSEYEVFV PSRYKFNASLCLDGIDWAVLEELIKNYTEENKPRHKSACDRSCIIGLAVLAALVLTALIA VMWLTSKRRRLAAVVAPVHPKIKSTLDEDEEEMETTNPLEVKDEQRARDMY (SEQ ID NO: 39) Tc_MARK_6973 >Tc_MARK_6973 | Trypanosoma cruzi marinkellei strain B7 | hypothetical protein, conserved | protein | length=599 QGIINDKTIIYFVEGQSSLRYITADYVHTVTISTKLSFTDVKLYGGKLYMTEQTKDEIWV CDIDMNGVPVTCVLQNGFKCDYGKYHGITVTKLGVFVVGESASGICHFDMHGNKISVLGG NYVDVYSLPTDTLFVMSFTELLHLRVVGSMMVVEKFAGRVDATCPPLLDGYDFTLCMNLR LFVIDQNEMYLATKLNTVRSITLPPWVWMELPPPPFPLGFPDDDEKKENVMHKIIQLMN EELNAHLRTQGTYVSLETMQVNDDTWNTKFAVMVQQQDFESATTPAEVLSTDFVQTKKFI M DYYN RVN EVLYM DTSIIPFCDQTM LLQMM H KLVAIVRNVLGFPLIYANPPEALKDFH1E NITIMKLLMPASFNNDTTRDALMDTDMDAALLQVLRELYGPDHWTLIFPMPKYEFSKLT DEQLIQVRWFILDLVRARLAECEILSVDSMDTSSQGTMCEATITNRTETVVPTPPFNLQS EYEVFVPSRYKFNVSVCLDGIDWVALEELIANYTEENKPRHKSACDRSCIIGLAVLTALV LTALIAVLWLTSKRRRLAAWAPVHPKFKSTLDEEEEEEMETSNPLEVKEEERTRDTY (SEQ ID NO: 40) Trypanosoma evansi TevSTIB805.5.5150 >TevSTIB805.5.5150 | Trypanosoma evansi strain STIB 805 | hypothetical protein, conserved | protein | length=807 MCFIFGVEMSNLAKRPMSLRKLPQLFLLIMIGIAFVAVECIGTPVKLPRRVDTVAGQFGV EGETNGYPNTTRLTEPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTYLRYNVGDSVIS GSSTINKPRSCVRRGSGNHTIIYFVDDQKDIKYIVGDDVSSFSVPTRGSLNAVAVHEGSL YVTDQNNKSVWKCGLGGAGKPQSCEEKKFTSVTLDAKPEGIAVTSKGIFVTARDSSNKGA LLWLDMSGSNRKGNVSGGFVDVFSTESGMLYAATEKELYTVTATDTSLSVTLFAGKNTSQ CYFPTNGEDIVLCDNSRLLVIEEYEMYVTSRAKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNYTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTVDGRRAGYADKPITFGSDVA ENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDITFPDPPFNFSAV VPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAADATARGKANVTLNTSGVKAND TGVGPNTTNTAGGANTTANVATNGTANVIVNPSTNATPTGTTNASVTNTTERAVPWAPT QPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVDIIDWRDLDEML NNRTDEVVEKSLSWCGHGCIIAFAVVGSLIAACLVVLAVVLTSKRRRLAAVVAPPRPKFV STVEDDEEDRVSNIGMPLTDGKGTTAP (SEQ ID NO: 41) TevSTIB805.5.5170 >TevSTIB805.5.5170 | Trypanosoma evansi strain STIB 805 | hypothetical protein, conserved | protein | length=818 MCFIFGVEMSNLAKRPMSLRKLPQLLLLIMIGIAFVAVECIGAPVKLPRRVDTVAGQFGF DGTTDGSSNVSMLSSPYALCRGRTNDEILVGSSNSFRNYSRKTKETGTFLRGGPTGGLVS ADAKISKPRSCVRRGSGNHTIIYFVDDQNGLKYINDNEIQHVTVGNGLSLTSVAIYEKDL YVTDQNNKSVWRCNVGGAGKPQNCEEKKFTGLTFTAKPEGIAVTSKGIFVAARDSSNKGA LLWLDMNGGGSKGNVSGGFVDVFSTESGMLYAATEKELYTVTATDTSFSVTSFAGKNTSS CYSHANGEDIVLCDNSRLLVIEEYEMYVTSKEKHTMRALTLPPVNLTAIFRGRPAPVGYP NTTIMEQFVASLTEDVNKALGTNDSYVDPDSVRVDPDTWETNYTVFVQQTRFDNTTEEKL RSLTYTQTDKTVDEYYGLTDEYVYIDTVLVPFCDDASLVTIQRALAREAGRALNFSLIYA DKPITFGSDVAENVTAVKLLMPHSFKNATTPKQLSAANLTDFAHNLVKDLRASDTRVDIT FPDPPFNFSAVVPEREQEVRWFVHGKVMKQLEICERLGSQGDAAVIAAAADATARGKANV TLNTSGVKANDTGVGPNTTNTAGGANTTANWANGTANVIVNPSTNATPTGTSNASVTNT TERAVPWAPTQPSNGYAECRSAITNRTETQNMEPPYDRKHRYEVFLPKKYDFNVSWCVD IIDWRDLDEMLNNRTDEWEKSLSWCGHGCIIAFAVVGSLIAACLWLAWLTSKRRRLA AWAPPRPKFVSTVEDDEEDRVSNIGVPLTDGKGTTAP (SEQ ID NO: 42) TevSTIB805.8.4170 >TevSTIB805.8.4170 | Trypanosoma evansi strain STIB 805 | hypothetical protein, conserved | protein | length=750 MPLWKQTNCEVETMNVREWGTVHLGYVSQMLLLVATVETIVVRSGAAPIELKRHVTTVA GKYGHIGDKDGFPGMSELSSPHAMCRGRNSDEILLGTVDRFRAFSRKNRETTTITAWETD EDQNSGSRSVKVDKPRACVQWTVGDSTFVYFVESMGEVKYFKDSGVFSHDVVRNGSLTGV ALYGNHLYLTEQNTNTVWTCEVGSDGDPIACHSHVALSAKCSIYGPIGIAATQQGIFVVA RGPAKQGTICWFDLQGHKIAEVDGEYVDITSTRSGDLLAATQNELHRVSTDGNKLTTKRF AGGSTNSCLPNTEGDDTLLCEITRLLVVTEYEMYVTSEKKSVLRSVTLPPVYVQGVFPGR PLPVGYPDKDIMEWIVGNLTEDINTALGTTESIVASSSVHVDSTTWLTNFTAGVQQPDFD DEKTEQALHKSNYEHTKEAADEYYNLTDEQVYMDSTMVPYCNRLSLDALRRKLAKEAGEV LNFTLIYADMPLKAESSDAGNITTVKLLMPASFNNTVTHDLLSDANLTETAHSFIKYLRS SDTHVDVTFSNPPFNFSSLTPDEEQEVRWYIHDEVMNQIKKCEERSTGRSMARREEVGDY SRTTIATALDSNVTGVCQSTITNRTVSLFYQPPYVEMSLYEVFIPGNYTFDVSECVGEID WQDLNDHLNNDTVRPTTEKAPKCGRVCLIIIAVVCALIVAVLIVLAWFTSKRRRLAAVV APARPKFVSTLDEDEQDYASAYGNKERVEQ (SEQ ID NO: 43) TevSTIB805.8.4220 >TevSTIB805.8.4220 | Trypanosoma evansi strain STIB 805 | hypothetical protein, conserved | protein | length=750 MPLWKQTNCEVETMNVREWGTVHLGYVSQMLLLVATVETIWRSGAAPIELKRHVTTVA GKYGHIGDKDGFPGMSELSSPHAMCRGRNSDEILLGTVDRFRAFSRKNRETTTITAWETD EDQNSGSRSVKVDKPRACVQWTVGDSTFVYFVESMGEVKYFKDSGVFSHDWRNGSLTGV ALYGNHLYLTEQNTNTVWTCEVGSDGDPIACHSHVALSAKCSIYGPIGIAATQQGIFVVA RGPAKQGTICWFDLQGHKIAEVDGEYVDITSTRSGDLLAATQNELHRVSTDGNKLTTKRF AGGSTNSCLPNTEGDDTLLCEITRLLVVTEYEMYVTSEKKSVLRSVTLPPVYVQGVFPGR PLPVGYPDKDIMEWIVGNLTEDINTALGTTESIVASSSVHVDSTTWLTNFTAGVQQPDFD DEKTEQALHKSNYEHTKEAADEYYNLTDEQVYMDSTMVPYCNRLSLDALRRKLAKEAGEV LNFTLIYADMPLKAESSDAGNITTVKLLMPASFNNTVTHDLLSDANLTETAHSFIKYLRS SDTHVDVTFSNPPFNFSSLTPDEEQEVRWYIHDEVMNQIKKCEERSTGRSMARREEVGDY SRTTIATALDSNVTGVCQSTITNRTVSLFYQPPYVEMSLYEVFIPGNYTFDVSECVGEID WQDLNDHLNNDTVRPTTEKAPKCGRVCLIIIAWCALIVAVLIVLAWFTSKRRRLAAW APARPKFVSTLDEDEQDYASAYGNKERVEQ (SEQ ID NO: 44) Examples of Leishmania species include: Leishmania aethiopica, Leishmania amazonensis, Leishmania arabica. Leishmania aristidesi, Leishmania donovani, Leishmania forattinii, Leishmania gerbiiii, Leishmania infantum, Leishmania kiliicki, Leishmania major, Leishmania mexicana, Leishmania pifanoi, Leishmania tropica, Leishmania turanica, Leishmania venezeutensis, Leishmania waltoni, Leishmania enriettii, Leishmania macropodum, Leishmania martiniquensis, Leishmania orientaiis, Leishmania adieri, Leishmania agamae, Leishmania ceramodactyli, Leishmania gulikae, Leishmania gymnodactyli, Leishmania heiioscopi, Leishmania hemidactyli, Leishmania hoogstraali, Leishmania nicollei, Leishmania platycephaia, Leishmania phnynocephaii, Leishmania senegafensis, Leishmania sofieffi. Leishmania tarento / ae, Leishmania zmeevi, Leishmania zuckermani, Leishmania bmziiiensis, Leishmania guyanensis Leishmania lamsoni. Leishmania iindenbergi, Leishmania naiffi, Leishmania panamensis, Leishmania peruviana, Leishmania shawi and Leishmania utingensis. In one embodiment, the trypanosomal vaccine is a Leishmania aethiopica, Leishmania amazonensis, Leishmania braziliensis, Leishmania donovani, Leishmania infantum, Leishmania major, Leishmania mexicana, Leishmania panamensis or Leishmania tropica vaccine. Examples of FLA1 binding proteins from Leishmania aethiopica, Leishmania amazonensis, Leishmania braziliensis, Leishmania donovani, Leishmania infantum, Leishmania major, Leishmania mexicana, Leishmania panamensis or Leishmania tropica include the following: Leishmania aethiopica LAEL147_00013770 0 >LAEL147_000137700 | Leishmania aethiopica L147 | hypothetical protein, conserved | protein | length=756 5 MGRCIRRVPAAAAAALLLALVAAAAVSTTTARAYDHAGITVAGAIMVGQNLQGKAGASRILNPFAICANFDTADV EDTTLLIGGASYFFTLNRYSTYLGFWYGQGSVNLNSGPIDKVRLTGVFGCVTLRPNSSNSLVTSTVYYVQNDG MLYWVSNSVVYLTPVKHGISFVDVTVHDNNVYLLSTQNHIYRCGIGAGGAVVGSACTQITLTGSTKFDQLITTPS DFRGFWSSCGIFIAPNSDLYWFNLSGVFIAKSAGVTFVDIKLTSNRDTANRGTPVLMAASTSAVYAVTASSATIS YTLVSGKETKSCNPALNNVDSDTSPTFCGIARlYPLSTDMVYMTTGGASVVRAIIVGNTTISDTITRTPFPVYFLtP NPSIIPLILDGMNYELVGNSNIPFPYVAINHSTPEVDDGTWDTTFSVDVSNRFFSTVSSAAWSTPFMGSLHGLQ AYYNRTNQILFGDPNVLPMCNLTKMQMIERAVAADARAALQYPYIYTSKAQNFTVNAHPNLTLLKLLMPYPFGEI LNESGFFENTTTPAALANVHFNTTMLAAVRNAYTPDFVYDCIFAGNAFPFHILTAAQQQLVRWIIYTAIQEQLAKC AENSPSYTGSDSSSSDSHDDMVPGCVPRVGIGNLTELVMPGMPYSNYNITVFIPEGLHYNFSISRCLDGTDWT NVTDYLQHATTPRTRQCGTGCIVSIAVVSAWAAILVVAIVIATSKRRRLATVVAPAFTVEPKFASTLDMSSEEGS RNPLNG (SEQ ID NO: 45) Leishmania amazonensis LAMA_000162600 >LAMA_000162600 | Leishmania amazonensis MHOM / BR / 71973 / M2269 | hypothetical protein, conserved | protein | length=755 MGRSIRRVSAAAAALLMALVAAAAVAPTTARAYDHAGITVAGALMVGQNLQGTAATSRIL NPFAICANFDTADVEDTTLLIGGASYFFTLNRYSTYLGFWYGQGSMNLNSGPIDKVRLTG VFGCVTLRPNPSNGLPTSIVYYVQNDGFLYWVSNSIVYLTQVESGISLFDVTVYNNSVYL LSAQNVIYRCGIGAGGAWGSACTQILLTGSPAFHQLIAVSSDFRGFAVSASGIVVAPTA DLFWFNLSGAFISKSAGVTFVDAKFTTNRDTANRGAPVLMAASTSAVYTVATSGPSITYT LVSGEETGRCNPALNNVDSDTSPTFCGIARIYPLSTDMVYMTTGGASVVRAILVGNTTVH DTITRTPFPVYFLDNSSIMPLMLDGMNYELVANSDIPFPYVAINEFTPEVGDSTWDTSFS VDVSNRFFSTASSAAVISTPFMGSLHGLQAYYNRTNQILFGDPNVLPMCNLTKMHMIERA VAADARAALQYPYIYTSRAQNFTVNAQPNLTLLKLLMPYPFGEILNESGFFENTTTPAAL ANVHFNKTMLAAVRNAYAPDFVYDSIFAGNAFPFHILTAAQQQWRWVIYMAIQEQU\KC AENTPSYPDSDSSSSDSHDDMVPGCVPRVGISNLTEQMIPGLPYSNFNITFFIPESLHYT FSISRCLDGTDWTNVTDYLQNATITSTRECGTGCIVSIAVASAVVAAILWVIVIVTSKR RRLATVVAPALTVEPKFASTLDVTSEEGSRNPLNG (SEQ ID NO: 46) Leishmania braziliensis LBRM2903_100015700 >LBRM2903_100015700 | Leishmania braziliensis MHOM / BR / 75 / M2903 | hypothetical protein, conserved | protein | length=756 MGRCVYRVSSAAATLLTVLIAAVTVAATTARAYDHAGVTVAGALLVGQNEEGKLGTNRIL NPFALCANFDTTDVTDTTLLIGGASYFFTFDRHSTYLSFWYGQGSMNLNSGPIDQVRLTG VFGCTTVRTTSSSGSPISAVYYVQNDGFLYVWMNSVVYVTLVKNGISLFDVTVYKGNLYL LSAQNRIYKCLIGPGGAVTGSACTQVMLTGSTAYANLSETSTSEFKGFAVSSAGIFIAPS SSLYWFNLAGGYIASTTTAVVFVDVKFTSNRDTANPGIPTLMAASTSAVYRVSTAGTSIT YTLIAGKETATCNLALDNVDSLTDPSFCGIARIYPLSLDWYMTTAGASVVRAIWSNTT IRDTITRTPFPLYFLDRASTIPVLLDGMNYEIVGHSNVPFPYVAIDQSTPEVNDTTWDTS FGVDISNRFFSMASSAAVTSTPFMGSLHGLETYYNRTNQIIFGDPNVLPMCNLTKMLMIE RAVATAARAALKYPYIYTSNAQNFTVNAQPNLTLVKLLMPYAFGEILNELGFFENTTTAA ALAAVQFNTTMLAAVRSAYMMDRVYDCIFSGNAYPFHVLTAAQQQEVRWIIYSAIQNQLA RCNQSIPYLVPDSNSSNSYNNMAPGCVPRIGINNLTEMLLPGLPYSNFNITVFIPESLYY NFGISRCLDGTDWTDVMGYLINATTRNNRKCNTGCIVGIAVASALVASFLVVAIVIMTSK RRRLATVVAPAATSEPKFISTLDMTSEEGSRNPLTR (SEQ ID NO: 47) LbrM.10.0760 >LbrM.10.0760 | Leishmania braziliensis MHOM / BR / 75 / M2904 | FLA1-binding protein | protein | length=756 MGRCVYRVSSAAATLLTVLIAAVTVAATTARAYDHAGVTVAGALLVGQNEEGKLGTNRIL NPFALCANFDTTDVTDTTLLIGGASYFFTFDRHSTYLSFWYGQGSMNLNSGPIDQVRLTG VFGCTTVRTTSSSGSPISTVYYVQ N DG FLYWVM NSVVYVTLVKNGISLFDVTVYKG N LYL LSAQNRIYKCLIGPGGAVTGSACTQVMLAGSTAYANLSETSTSEFKGFAVSSAGIFIAPS SSLYWFNLAGGYIASTTTAVVFVDVKFTSNRDTANPGIPTLMAASTSAVYRVSTAGTSIT YTLIAGKETATCNLALDNVDSLTDPSFCGIARIYPLSLDVVYMTTAGASWRAIVVSNTT IRDTITRTPFPLYFLDRASTIPVLLDGMNYEIVGHSNVPFPYVAIDQSTPEVNDTTWDTS FGVDISNRFFSMASSAAVTSTPFMGSLHGLETYYNRTNQIIFGDPNVLPMCNLTKMLMIE RAVATAARAALKYPYIYTSNAQNFTVNAQPNLTLVKLLMPYAFGEILNELGFFENTTTAA ALAAVQFNTTMLAAVRSAYMMDRVYDCIFSGNAYPFHVLTAAQQQEVRWIIYSAIQNQLA RCNQSIPYLGPDSNSSNSYNNMAPGCVPRIGINNLTEMLLPGLPYSNFNITVFIPESLYY NFGISRCLDGTDWTDVMGYLINATTRNNRKCNTGCIVGIAVASALVASFLWAIVIMTSK RRRLATVVAPAATSEPKFISTLDMTSEEGSRNPLTR (SEQ ID NO: 48) LbrM.10.2.000760 >LbrM. 10.2.000760 | Leishmania braziliensis MHOM / BR / 75 / M2904 2019 | hypothetical protein, conserved | protein | length=756 MGRCVYRVSSAAATLLTVLIAAVTVAATTARAYDHAGVTVAGALLVGQNEEGKLGTNRIL NPFALCANFDTTDVTDTTLLIGGASYFFTFDRHSTYLSFWYGQGSMNLNSGPIDQVRLTG VFGCTTVRTTSSSGSPISTVYYVQNDGFLYWVMNSVVYVTLVKNGISLFDVTVYKGNLYL LSAQNRIYKCLIGPGGAVTGSACTQVMLAGSTAYANLSETSTSEFKGFAVSSAGIFIAPS SSLYWFNLAGGYIASTTTAWFVDVKFTSNRDTANPGIPTLMAASTSAVYRVSTAGTSIT YTLIAGKETATCNLALDNVDSLTDPSFCGIARIYPLSLDWYMTTAGASVVRAIWSNTT IRDTITRTPFPLYFLDRASTIPVLLDGMNYEIVGHSNVPFPYVAIDQSTPEVNDTTWDTS FGVDISNRFFSMASSAAVTSTPFMGSLHGLETYYNRTNQIIFGDPNVLPMCNLTKMLMIE RAVATAARAALKYPYIYTSNAQNFTVNAQPNLTLVKLLMPYAFGEILNELGFFENTTTAA ALAAVQFNTTMLAAVRSAYMMDRVYDCIFSGNAYPFHVLTAAQQQEVRWIIYSAIQNQLA RCNQSIPYLGPDSNSSNSYNNMAPGCVPRIGINNLTEMLLPGLPYSNFNITVFIPESLYY NFGISRCLDGTDWTDVMGYUNATTRNNRKCNTGCIVGIAVASALVASFLVVAIVIMTSK RRRLATVVAPAATSEPKFISTLDMTSEEGSRNPLTR (SEQ ID NO: 49) Leishmania donovani <*• >LdBPK_100670.1 | Leishmania donovani BPK282A1 | FLA1-binding protein | protein MGRCIRRVSSAAAAALLIALAAAAAVATTTARAYDHAGITVAGALLVGQNLQGKAGASRI LNPFAICADFDTADVEDTTLLIGGASYFFSFNRYSTYLGFWYGQGSMNLNSGPIDKVRLT GVFGCVTLRPNSSNGLVTSTVYYVQNDGMLYVWSNSWYLTQVKHGISFVDVTVHDNNVY LLSTQNGIYQCGIGAGGAWGSACTQITLTGSTEFHQLIPISSDFRGFAVSSSGIFITPT SDLYWFNLSGAFIAKSVGVTFVDTKFTSSRDTANRGTSVLMAASTSAVYTVTTSDATISY ALVSGKEVKSCNPALNNVDSDTSPTFCGIARIYPLSTDMVYMTTGGASWRAIIVSNTTI length=756 LdBPK_100670.1 SDTITRTPFPVYFLDNSSIMPULDGMNYELVSNSNIPFPYVAINHSTPKVDDSTWDTIF SVDVSNRFFSTVSRAAVIGTPFMSSLHGLQAYYNRTNHILFGDPNVLPMCNLTKMQMIER AVAADARAALQYPYIYTSKAQN FTVN AH PN LTLLKLLM PYPFG El LN ESGFFENTTTPAS LANVHFNTTMLAAVRNAYTPDFVYDCIFAGNAFPFHILTAAQQQLVRWIIYTAIQEQLAK CAENSPSYTGSGSSSSDSHDDMVPGCVPRVGIDNLTELVMPGMPYSNYNITVFIPESLHY NFSISRCLDGTDWTNVTDYLQNATTTRTRKCGTGCIVSIAVVSAVVAAILWAIVIATSK RRRLATVVAPALTVEPKFASTLDMGSEEGSRNPLNG (SEQ ID NO: 50) LdCL_100013500 >LdCL_100013500 | Leishmania donovani CL-SL | hypothetical protein | protein | length=756 MGRCIRRVSSAAAAALLIALAAAAAVATTTARAYDHAGITVAGALLVGQNLQGKAGASRI LNPFAICADFDTADVEDTTLLIGGASYFFSFNRYSTYLGFWYGQGSMNLNSGPIDKVRLT GVFGCVTLRPNSSNGLVTSTVYYVQNDGMLYWVSNSWYLTQVKHGISFVDVTVHDNNVY LLSTQNGIYQCGIGAGGAWGSACTQITLTGSTEFHQLIPISSDFRGFAVSSSGIFITPT SDLYWFNLSGAFIAKSVGVTFVDTKFTSSRDTANRGTSVLMAASTSAVYTVTTSDATISY ALVSGKEVKSCNPALNNVDSDTSPTFCGITRIYPLSTDMVYMTTGGASWRAIIVSNTTI SDTITRTPFPVYFLDNSSIMPLILDGMNYELVSNSNIPFPYVAINHSTPKVDDSTWDTIF SVDVSNRFFSTVSRAAVIGTPFMSSLHGLQAYYNRTNHILFGDPNVLPMCNLTKMQMIER AVAADARAALQYPYIYTSKAQNFTVNAHPNLTLLKLLMPYPFGEILNESGFFENTTTPAS LANVHFNTTMLAAVRNAYTPDFVYDCIFAGNAFPFHILTAAQQQLVRWIIYTAIQEQU\K CAENSPSYTGSGSSSSDSHDDMVPGCVPRVGIDNLTELVMPGMPYSNYNITVFIPESVHY NFSISRCLDGTDWTNVTDYLQNATTTRTRKCGTGCIVSIAVVSAWAAILWAMATSK RRRLATVVAPALTVEPKFASTLDMGSEEGSRNPLNG (SEQ ID NO: 51) LdBPK.10.2.000670 >LdBPK. 10.2.000670 | Leishmania donovani strain LV9 | hypothetical protein, conserved | protein | length=756 MGRCIRRVSSAAAAALLIALAAAAAVATTTARAYDHAGITVAGALLVGQNLQGKAGASRI LNPFAICADFDTADVEDTTLLIGGASYFFSFNRYSTYLGFWYGQGSMNLNSGPIDKVRLT GVFGCVTLRPNSSNGLVTSTVYYVQNDGMLYWVSNSWYLTQVKHGISFVDVTVHDNNVY LLSTQNGIYQCGIGAGGAWGSACTQITLTGSTEFHQLIPISSDFRGFAVSSSGIFITPT SDLYWFNLSGAFIAKSVGVTFVDTKFTSSRDTANRGTSVLMAASTSAVYTVTTSDATISY ALVSGKEVKSCNPALNNVDSDTSPTFCGIARIYPLSTDMVYMTTGGASWRAIIVSNTTV SDTITRTPFPVYFLDNSSIMPLILDGMDYELVSNSNIPFPYVAINHSTPKVDDSTWDTIF SVDVSNRFFSTVSRAAVIGTPFMSSLHGLQAYYNRTNHILFGDPNVLPMCNLTKMQMIER AVAADARAALQYPYI YTSKAQN FTVN AH PN LTLLKLLM PYPFG El LN ESGFFENTTTPAS LANVHFNTTMLAAVRNAYTPDFVYDCIFAGNAFPFHILTAAQQQLVRWIIYTAIQEQLAK CAENSPSYTGSGSSSSDSHDDMVPGCVPRVGIDNLTELVMPGMPYSNYNITVFIPESLHY NFSISRCLDGTDWTNVTDYLQNATTTRTRKCGTGCIVSIAVVSAVVAAILWAIVIATSK RRRLATVVAPALTVEPKFASTLDMGSEEGSRNPLNG (SEQ ID NO: 52) Leishmania infantum LI NF_100013000 > LI NF_100013000 | Leishmania infantum JPCM5 | hypothetical protein - conserved | protein | length=756 MGRCIRRVSSAAAAALLIALAAAAAVATTTARAYDHAGITVAGALLVGQNLQGKAGASRI LNPFAICADFDTADVEDTTLLIGGASYFFSFNRYSTYLGFWYGQGSMNLNSGPIDKVRLT GVFGCVTLRPNSSNGLVTSTVYYVQNDGMLYWVSNSWYLTQVKHGISFVDVTVHDNNVY LLSTQNGIYQCGIGAGGAWGSACTQITLTGSTEFHQLIPISSDFRGFAVSSSGIFITPT SDLYWFNLSGAFIAKSVGVTFVDTKFTSSRDTANRGTSVLMAASTSAVYTVTTSDATISY ALVSGKEVKSCNPALNNVDSDTSPTFCGIARIYPLSTDMVYMTTGGASWRAIIVSNTTV SDTITRTPFPVYFLDNSSIMPLILDGMNYELVSNSNIPFPYVAINHSTPKVDDSTWDTIF SVDVSNRFFSTVSRAAVIGTPFMSSLHGLQAYYNRTNHILFGDPNVLPMCNLTKMQMIER AVAADARAALQYPYI YTSKAQN FTVNAH PN LTLLKLLM PYPFGEl LN ESGFFENTTTPAS LANVHFNTTMLAAVRNAYTPDFVYDCIFAGNAFPFHILTAAQQQLVRWIIYTAIQEQLAK CAENSPSYTGSGSSSSDSHDDMVPGCVPRVGIDNLTELVMPGMPYSNYNITVFIPESLHY NFSISRCLDGTDWTNVTDYLQNATTTRTRKCGTGCIVSIAVVSAVVAAILWAIVIATSK RRRLATVVAPALTVEPKFASTLDMGSEEGSRNPLNG (SEQ ID NO: 53) Leishmania major LmjF. 10.0620 >LmjF.10.0620 | Leishmania major strain Friedlin | FLA1-binding protein | protein | length=757 MGRCIRRVSALKAAAALLLALVAAAAVATTTARAYDHAGITVAGAILVGQNLQGKAGASR ILNPFAICANFDTTDAEDTTLLIGGASYFFTLNRYSTYLGFWYGQGSMNLNNGPIDKVRL TGVFGCVTLRPNSSNGLVTSTVYYVQNDGMLYWVSNSVVYLTQVKYGISFVDVTVHDNNV YLLSNQNEIYWCGIGAGGTWGSACTHITLTGSTEFHQLITVSSDFRGFAVSSSGIFIAP TSDLYWFNLSGVFIAKSAGVTFVDTKFTSSRDTVNRETPVLMAASTSAVYSVTTSGATIS YTLVSGKETKSCNPALSNVDSDTSPTFCGIARIYPLNTDTVYMTTGGASWRAIIVSNTT ISDTITRTPFPVYFLDNSSIIPLILDGMNYELVGNSNIPFPYVAINHSTPEVDDSTWDTT FSVDVSNRFFSSVSSAAWSTPFMGSLHGLQAYYNRTNQILFGDPNVLPMCNLTKMLMIE RAVAADARAALQYPYIYTSKAQNFTVNAHPNLTLLKLLMPYPFGEILNESGFFENTTTPA ALANVHFNTTMU\AVRNAYTPDFVYDCIFAGNAFPFYILTAAQQQLVRWIIYTAIQEQLA KCAENNPSYTGSDSSSSDSHDDMVPGCVPRVGISNLTELVMPGMPYSNYNIAVFIPESLH YNFSISRCLDGTDWTNVTEYLQQATVARTRKCGTGCIVSIAWSAWAAILWAIVIATS KRRRLATVVAPALTVEPKFASTLDVSSEEGSRNPLNG (SEQ ID NO: 54) LMJLV39_100012300 >LMJLV39_100012300 | Leishmania major strain LV39c5 | hypothetical protein, conserved | protein | length=757 MGRCIRRVSALKAAAALLLALVAAAAVATTTARAYDHAGITVAGAILVGQNLQGKAGASR ILNPFAICANFDTTDAEDTTLLIGGASYFFTLNRYSTYLGFWYGQGSMNLNNGPIDKVRL TGVFGCVTLRPNSSNGLVTSTVYYVQN DGM LYVWSNSWYLTQVKYGISFVDVTVH DN NV YLLSNQNEIYWCGIGAGGTWGSACTHITLTGSTEFHQLITVSSDFRGFAVSSSGIFIAP TSDLYWFNLSGVFIAKSAGVTFVDTKFTSSRDTVNRETPVLMAASTSAVYSVTTSGATIS YTLVSGKETKSCNPALSNVDSDTSPTFCGIARIYPLNTDTVYMTTGGASWRAIIVSNTT ISDTITRTPFPVYFLDNSSIIPLILDGMNYELVGNSNIPFPYVAINHSTPEVDDSTWDTT FSVDVSNRFFSSVSSAAWSTPFMGSLHGLQAYYNRTNQILFGDPNVLPMCNLTKMLMIE RAVAADARAALQYPYIYTSKAQNFTVNAHPNLTLLKLLMPYPFGEILNESGFFENTTTPA ALANVHFNTTMLAAVRNAYTPDFVYDCIFAGNAFPFYILTAAQQQLVRWIIYTAIQEQLA KCAENNPSYTGSDSSSSDSHDDMVPGCVPRVGISNLTELVMPGMPYSNYNIAVFIPESLH YNFSISRCLDGTDWTNVTEYLQQATVARTRKCGTGCIVSIAWSAWAAILVVAIVIATS KRRRLATVVAPALTVEPKFASTLDVSSEEGSRNPLNG (SEQ ID NO: 55) LMJSD75_100012400 >LMJSD75_100012400 | Leishmania major strain SD 75.1 | hypothetical protein, conserved | protein | length=757 MGRCIRRVSALKAAAALLLALVAAAAVATTTARAYDHAGITVAGAILVGQNLQGKAGASR ILNPFAICANFDTTDAEDTTLLIGGASYFFTLNRYSTYLGFWYGQGSMNLNNGPIDKVRL TGVFGCVTLRPNSSNGLVTSTVYYVQNDGMLYWVSNSWYLTQVKYGISFVDVTVHDNNV YLLSNQNEIYWCGIGAGGTWGSACTHITLTGSTEFHQLITVSSDFRGFAVSSSGIFIAP TSDLYWFNLSGVFIAKSAGVTFVDTKFTSSRDTVNRETPVLMAASTSAVYSVTTSGATIS YTLVSGKETKSCNPALSNVDSDTSPTFCGIARIYPLNTDTVYMTTGGASWRAIIVSNTT ISDTITRTPFPVYFLDNSSIIPLILDGMNYELVGNSNIPFPYVAINHSTPEVDDSTWDTT FSVDVSNRFFSSVSSAAWSTPFMGSLHGLQAYYNRTNQILFGDPNVLPMCNLTKMLMIE RAVAADARAALQYPYIYTSKAQNFTVNAHPNLTLLKLLMPYPFGEILNESGFFENTTTPA ALANVHFNTTMLAAVRNAYTPDFVYDCIFAGNAFPFYILTAAQQQLVRWIIYTAIQEQLA KCAENNPSYTGSDSSSSDSHDDMVPGCVPRVGISNLTELVMPGMPYSNYNIAVFIPESLH YNFSISRCLDGTDWTNVTEYLQQATVARTRKCGTGCIVSIAWSAWAAILVVAIVIATS KRRRLATVVAPALTVEPKFASTLDVSSEEGSRNPLNG (SEQ ID NO: 56) Leishmania mexicana LmxM.10.0620 >LmxM. 10.0620 | Leishmania mexicana MHOM / GT / 2001 / U1103 | FLA1-binding protein | protein | length=755 MGRCIRRVSAAAAALLMALVAAAAVAPTTARAYDHAGITVAGALMVGQNLQGTAGTSRIL NPFAICANFDTADVEDTTLLIGGASYFFTLNRYSTYLGFWYGQGSMNLNSGPIDKVRLTG VFGCVTLRPNPSNALPTSIVYYVQNDGFLYWVSNSIVYLTQLESGISLFDVTVYNNSVYL LSAQNVIYRCGIGAGGAVVGSACTQIPLTGSPAFHQLITVSSDFRGFAVSASGIVVAPTA DLFWFDLSGAFISKSAGVTFVDAKFTTNRDTANRGAPVLMAASTSAVYTVATSGASITYT LVSGEETGRCNPALNNVDSDTSPTFCGIARIYPLSTDMVYMTTGGASVVRAILVGNTTVR DTITRTPFPVYFLDNSSIMPLMLDGMNYELVANSDIPFPYVAINESTPEVADSTWDTSFS VDVSNRFFSTASSAAVTSTPFMGSLHGLQAYYNRTNQILFGDPNVLPMCNLTKMHMIERA VAADARAALQYPYIYTSRAQNFTVNAQPNLTLLKLLMPYPFGEILNESGFFENTTTPAAL ANVHFNKTMLAAVRNAYAPDFVYDSIFAGNAFPFHILTAAQQQWRWVIYMAIQEQLAKC AENTPSYPGSDSSSSDSQDDMVPGCVPRVGISNLTEQMIPGLPYSNFNITVFIPESLHYT FSISRCLDGTDWTNVTDYLQNATITTTRKCGTGCIVSIAVASAVVAAILWAIVIVTSKR RRLATVVAPALTVEPKFASTLDATSEEGSRNPLNG (SEQ ID NO: 57) Leishmania panamensis LPAL13_100012300 >LPAL13_100012300 | Leishmania panamensis MHOM / COL / 81 / L13 | hypothetical protein, conserved | protein | length=756 MGRCVYRVSSAAATLLTVLIAAVTVAATTARAYDHAGVTVAGALLVGQNEEGKLGTNRIL NPFALCANFDTTDVTDTALLIGGASYFFTFDRHSTYLSFWYGQGSMNLNSGPIDQVRLTG VFGCTTVRTTSSSGSPISTVYYVQNDGFLYWVMNSVVYVTLVKNGISLFDVTVYKGNLYL LSAQNSIYKCLIGPGGAVTGSACTQVMLAGSTAYANLSETSTSEFKGFAVSSAGIFIAPS SSLYWFNLAGGYIASTTTAWFVDVKLTSNRDTANPGIPTLMAASTSAVYRVSTAGTSIT YTLIAGKETATCNLALDNVDSLTDPSFCGIARIYPLSLDWYMTTAGASWRAIVVSNTT IRDTITRTPFPLYFLDRASTIPVLLDGMNYEIVGHSNVPFPYVAIDQSTPEVNDTTWDTS FGVDISNRFFSMASSAAVTSTPFMGSLHGLETYYNRTNQIIFGDPNVLPMCNLTKMLMIE RAVATAARAALKYPYIYTSNAQNFTVNAQPNLTLVKLLMPYAFGEILNELGFFENTTTAA ALAAVQFNTTMLAAVRSAYMMDRVYDCIFSGNAYPFHVLTAAQQQEVRWIIYSAIQNQLA RCNQSIPYLGPDSNSSNSYNNMAPGCVPRIGINNLTEMLLPGLPYSNFNITVFIPESLYY NFGISRCLDGTDWTDVMGYLINATTRNNRKCNTGCIVGIAVASALVASFLWAIVIMTSK RRRLATVVAPAATSEPKFISTLDMTSEEGSRNPLTR (SEQ ID NO: 58) LPMP_100580 >LPMP_100580 | Leishmania panamensis strain MHOM / PA / 94 / PSC-1 | hypothetical protein | protein | length=756 MGRCVYRVSSAAATLLTVLIAAVTVAATTARAYDHAGVTVAGALLVGQNEEGKLGTNRIL NPFALCANFDTTDVTDTALLIGGASYFFTFDRHSTYLSFWYGQGSMNLNSGPIDQVRLTG VFGCTTVRTTSSSGSPISTVYYVQN DG FLYWVM NSVVYVTLVKNGISLFDVTVYKG N LYL LSAQNSIYKCLIGPGGAVTGSACTQVMLAGSTAYANLSETSTSEFKGFAVSSAGIFIAPS SSLYWFNLAGGYIASTTTAVVFVDVKLTSNRDTANPGIPTLMAASTSAVYRVSTAGTSIT YTLIAGKETATCNLALDNVDSLTDPSFCGIARIYPLSLDVVYMTTAGASVVRAIVVSNTT IRDTITRTPFPLYFLDRASTIPVLLDGMNYEIVGHSNVPFPYVAIDQSTPEVNDTTWDTS FGVDISNRFFSMASSAAVTSTPFMGSLHGLETYYNRTNQIIFGDPNVLPMCNLTKMLMIE RAVATAARAALKYPYIYTSNAQNFTVNAQPNLTLVKLLMPYAFGEILNELGFFENTTTAA ALAAVQFNTTMLAAVRSAYMMDRVYDCIFSGNAYPFHVLTAAQQQEVRWIIYSAIQNQLA RCNQSIPYLGPDSNSSNSYNNMAPGCVPRIGINNLTEMLLPGLPYSNFNITVFIPESLYY NFGISRCLDGTDWTDVMGYLINATTRNNRKCNTGCIVGIAVASALVASFLWAIVIMTSK RRRLATVVAPAATSEPKFISTLDMTSEEGSRNPLTR (SEQ ID NO: 59) Leishmania tropica LTRL590_100007000 >LTRL590_100007000 | Leishmania tropica L590 | hypothetical protein, conserved | protein | length=757 MGRCIRRVPAAAAAAALLLALVAAAAVSTTTARAYDHAGITVAGAIMVGQNLQGKAGASR ILNPFAICANFDTADVEDTTLLIGGASYFFTLNRYSTYLGFWYGQGSMNLNSGPIDKVRL TGVFGCVTLRPNSSNGLVTSTVYYVQN DGM LYVWSNSWYLTQVTHGISFVDVTVH DN NV YLLSTQNRIYRCSIGTGGAVVGSACTQITLTGSTEFDQLITVPSDFRGFAVSSCGIFIAP TSDLYWFSLSGVFITKSAGVTFVDIKLTSSSDTANTGTSVFMAASTSAVYAVTASSATIS YALVSGKETKSCNPALNNVDSDTSPTFCGIARIYPLNTDMVYMTTGVASVVRAIIVSNTT ISDTITRTPFPVYFLDNSSIIPLILDGMNYELVGNSNIPFPYVAINHSTPEVDDSTWDTT FSVDVSNRFFSTVSSAAVVSTPFMGSLHGLQAYYNRTNQILFGDPNVLPMCNLTKMQRIE RAVAADARAALQYPYIYTSKAQNFTVNAHPNLTLLKLLMPYPFGEILNESGFFENTTTPA VLANVHFNTTMI_AAVRNAYTPDFVYDCIFAGNAFPFQILTAAQQQLVRWIIYTAIQEQI_A KCAENSPSYTGSDSSSSDSHDDMVPGCVPRVGIGNLTELVMPGMPYSNYNITVFIPEGLH YNFSISRCLDGTDWTNVTDYLQHATTPRTRKCGTGCIVSIAVVSAVVAAILVVAIVIATS KRRRLATVVAPAFTVEPKFASTLDMSSEEGSRNPLNR (SEQ ID NO: 60) According to a further aspect of the invention, there is provided a pharmaceutical composition comprising a trypanosomal vaccine as defined herein. Thus, such a pharmaceutical composition may also be referred to as a vaccine composition. In one embodiment, the vaccine composition additionally comprises invariant flagellum antigen. In one embodiment, the invariant flagellum antigen comprises the amino acid sequence as set forth in SEQ ID NO: 61, or a protein having at least 90% sequence identity to said amino acid sequence, or a fragment of said amino acid sequence thereof, or a nucleic acid molecule encoding said protein. The amino acid sequence of SEQ ID NO: 61 is an invariant flagellum antigen from T. vivax as detailed in WO 2020 / 144465, the contents of which are hereby incorporated by reference (in particular sequences, compositions and methods contained therein). Thus, in one embodiment the invariant flagellum antigen is from T. vivax. References herein to the amino acid sequence set forth in SEQ ID NO: 61 refer to: MRCHEPPTPPQLSATCCVAEEIDTYNKHLDALMQIIGDAIKNISTNEDNARARAEGLKGCNL HYVQFAVAHTEGSVVAARREAVKAQNTIKGSTSLLKKVTIDISNSFRNISSKCNELREKYPSL IPADKNSPPNITFKKAVQLYVKNFSTCNVMYAKKLLRLVAQSEKIEAEVSRAVERTNASTME LAKLDKVAVQLNKDITSNRTWAGCKLAEYHGQMNFVFMGFYVLLSDILDELHSLLKKSKSM QPTRLTQEEVRRALSKAEQVCHDVSRFVKSLGSTLRDFTNFVHRLRKEYLHGILRNASGFR ESFERCYKVATNNSVTRLESTVEEITANNENIAAWESMTVHQWKDVSKKLRQSLLTVLGGS NEYILLYGYFQEFDSMSVREFSNTVRAFRQSITEMSVARNWGVAAKTVAADRKRILCRSVL MFNKGTAGSESARKLYELCKTRMPVEEPDSSREDGVVGTSGSEEEISGKDGGTSFSVSDA DYWEWDVPPKVLEESSGDLLYDTAVDLHTKRKSPFYQVGS (SEQ ID NO: 61). The amino acid sequence of SEQ ID NO: 61 corresponds to the ectodomain of a cell surface T. vivax protein known as TvY486_0807240. The full length amino acid sequence of TvY486_0807240 is shown below: M EVM LFDYFH VLPISCKPRN FCIAFM LMFLRFCPVFAMRCHEPPTPPQLSATCCVAEEIDTY NKHLDALMQIIGDAIKNISTNEDNARARAEGLKGCNLHYVQFAVAHTEGSWAARREAVKAQ NTIKGSTSLLKKVTIDISNSFRNISSKCNELREKYPSLIPADKNSPPNITFKKAVQLYVKNFSTC NVMYAKKLLRLVAQSEKIEAEVSRAVERTNASTMELAKLDKVAVQLNKDITSNRTWAGCKL AEYHGQMNFVFMGFYVLLSDILDELHSLLKKSKSMQPTRLTQEEVRRALSKAEQVCHDVSR FVKSLGSTLRDFTNFVHRLRKEYLHGILRNASGFRESFERCYKVATNNSVTRLESTVEEITA NNENIAAWESMTVHQWKDVSKKLRQSLLTVLGGSNEYILLYGYFQEFDSMSVREFSNTVR AFRQSITEMSVARNVVGVAAKTVAADRKRILCRSVLMFNKGTAGSESARKLYELCKTRMPV EEPDSSREDGWGTSGSEEEISGKDGGTSFSVSDADYWEWDVPPKVLEESSGDLLYDTAV DLHTKRKSPFYQVGSIAFGVFLLWSCGVGILMFVRRWYAACVARSADGGTDC (SEQ ID NO: 62) wherein the underlined portion represents the ectodomain region of TvY486_0807240. TvY486_0807240 is also referred to herein as either V23 or IFX (invariant flagellum antigen from T. vivax). Data is presented herein which surprisingly shows that IFX together with TclL3000_0_35140 or TclL3000_0_17090 elicited protection in vaccinated animals to both T. congolense and T. vivax (see Example 4 and Figure 7). This, coupled with the remaining data presented herein, indicates that a vaccine composition comprising TclL3000_0_35140 or TclL3000_0_17090 together with IFX represents a good candidate for trypanosomal infection, such as animal African trypanosomiasis (AAT) caused by T. congolense and / or T. vivax. Thus, a composition comprising TclL3000_0_35140 or TclL3000_0_17090 together with IFX offers the possibility of vaccinating animals to provide protection against both T. congolense and T. vivax. In another embodiment, the vaccine composition comprises a protein which consists of the amino acid sequence as set forth in SEQ ID NO: 61. In a further embodiment, the vaccine composition additionally comprises one or more adjuvants. References herein to the term "adjuvant" refer to a compound that, when used in combination with a specific immunogen in a formulation, will augment or otherwise alter or modify the resultant immune response. Modification of the immune response can include intensification or broadening the specificity of either or both antibody and cellular immune responses. Modification of the immune response can also mean decreasing or suppressing certain antigen-specific immune responses. In one embodiment, at least about 1 ng and up to about 50 ng adjuvant is present within the vaccine composition. In a further embodiment, at least about 1 pg and up to about 20 pg adjuvant is present within the vaccine composition. Examples of suitable adjuvants include: alum; aluminum hydroxide; aluminum phosphate; calcium phosphate hydroxide; paraffin oil; killed bacteria such as Bordetella pertussis, Mycobacterium bovis and toxoids; squalene, detergents; plant saponins from quillaja, soybean, polygala senega; cytokines such as IL-1, IL-2, IL-12; Freund's complete adjuvant; and Freund's incomplete adjuvant. One further example of a suitable adjuvant includes TiterMax® Gold Adjuvant (Sigma-Aldrich) which 03 01 25 contains three essential ingredients: a block copolymer, CRL-8300, squalene (a metabolizable oil) and a sorbitan monooleate. In a yet further embodiment, said adjuvant comprises aluminium hydroxide, such as a wet gel 5 suspension of aluminium hydroxide, in particular Alhydrogel® (RTM), more particularly Alhydrogel® (RTM) 2%. In one particular embodiment, said adjuvant comprises Montanide® (RTM) ISA 201 VG. This adjuvant is a water-in-oil-in-water adjuvant and full details of this adjuvant may be found: https: / / www.seppic.com / montanide-isa-w-o-w. In an alternative embodiment, said adjuvant comprises Quil-A® (RTM). Quil-A® (RTM) adjuvant is a saponin 10 adjuvant which is used in a wide variety of veterinary vaccines. Fail details of Quil-A® (RTM) may be found: https: / / www.invivoqen.com / quila. In one embodiment, the vaccine composition additionally comprises a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof, in which the immunogen (i.e. the 15 proteins as defined herein) is / are suspended or dissolved. Pharmaceutically acceptable carriers are known, and include but are not limited to, water for injection, saline solution, buffered saline, dextrose, water, glycerol, sterile isotonic aqueous buffer, and combinations thereof. For parenteral administration, such as subcutaneous 20 injection, the carrier may include water, saline, alcohol, a fat, a wax, a buffer or combinations thereof. Pharmaceutically acceptable carriers, diluents, and other excipients are described in detail in Remington's Pharmaceutical Sciences (Mack Pub. Co. N.J. current edition). The formulation should suit the mode of administration. In a preferred embodiment, the formulation is suitable for administration to humans, preferably is sterile, non-particulate and / or non-25 pyrogenic. In other embodiments, the vaccine composition can include one or more diluents, preservatives, solubilizers and / or emulsifiers. For example, the vaccine composition can include minor amounts of wetting or emulsifying agents, or pH buffering agents to improve 30 vaccine efficacy. The composition can be a solid form, such as a lyophilized powder suitable for reconstitution, a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. 35 It may also be desirable to include other components in a vaccine composition, such as delivery vehicles including but not limited to aluminum salts, water-in-oil emulsions, biodegradable oil vehicles, oil-in-water emulsions, biodegradable microcapsules, and liposomes. In other embodiments, the vaccine composition can include antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. Administration of the vaccine composition can be systemic or local. Methods of administering a vaccine composition include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intravenous and subcutaneous), epidural, and mucosal (e.g., intranasal and oral or pulmonary routes or by suppositories). In a specific embodiment, compositions described herein are administered intramuscularly, intravenously, subcutaneously, transdermally or intradermally. The compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucous, colon, conjunctiva, nasopharynx, oropharynx, vagina, urethra, urinary bladder and intestinal mucosa, etc.) and may be administered together with other biologically active agents. In some embodiments, intranasal or other mucosal routes of administration of a composition may induce an antibody or other immune response that is substantially higher than other routes of administration. In another embodiment, intranasal or other mucosal routes of administration of a composition described herein may induce an antibody or other immune response at the site of immunization. In one embodiment, the vaccine composition has a volume of between about 50pl and about 10ml, such as 1ml. According to a further aspect of the invention, there is provided a method of preventing or treating trypanosomal infection in a mammal which comprises administering to the mammal a therapeutically effective amount of the vaccine composition as defined herein. References herein to “trypanosomal infection” refer to infection by a trypanosome as defined herein, in particular T. congolense. Thus, in one embodiment, the trypanosomal infection is an infection mediated by Trypanosoma congolense. In another embodiment, the the trypanosomal infection is an infection mediated by Trypanosoma vivax. In one embodiment, the trypanosomal infection is animal African trypanosomiasis (AAT). References herein to “effective amount” refer to a dose which is sufficient or most likely to elicit antibodies such that the immunized subject has reduced severity of infection. According to a further aspect of the invention, there is provided a method of inducing an immune response in a mammal, wherein the method includes administering to the mammal, an effective amount of the vaccine composition as defined herein. Examples of suitable mammals include ungulates, such as those selected from humans, cattle, goats, sheep, horses, pigs, dogs and camels. In one embodiment, the vaccine composition is administered in a single dose regimen. In another embodiment, the vaccine composition is administered in a two dose regimen that includes a first and a second dose. In one embodiment, the second dose is administered at least about 1 week, 2 weeks, 3 weeks, 1 month or 1 year after the first dose. In another embodiment, the vaccine composition is administered in a three dose regimen. According to a further aspect of the invention, there is provided a kit of parts comprising a vaccine composition as defined herein, a medical instrument or other means for administering the vaccine composition and instructions for use. In one embodiment, the vaccine composition is packaged in a hermetically sealed container such as an ampoule or sachette indicating the quantity of composition. In one embodiment, the composition is supplied as a liquid. In another embodiment, the composition is supplied as a dry sterilized lyophilized powder or water free concentrate in a hermetically sealed container, wherein the composition can be reconstituted, for example, with water or saline, to obtain an appropriate concentration for administration to a subject. When the vaccine composition is systemically administered, for example, by subcutaneous or intramuscular injection, a needle and syringe, or a needle-less injection device can be used. The vaccine formulation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. The invention is further described below with reference to the following examples. EXAMPLE 1 - Materials and Methods Design, synthesis and purification of T. congolense TclL3000_0_17090 and TclL3000_0_35140 The regions corresponding to the entire extracellular domains of TclL3000_0_17090 and TclL3000_0_35140 were determined by using transmembrane (TMHMMv2.0 (Sonnhammer et al., (1998) Proceedings International Conference on Intelligent Systems for Molecular Biology 6, 175-182) and signal peptide prediction software (SignalP v4.0 (Petersen et al., (2011) Nature methods 8, 785-786). Sequences encoding the entire extracellular domains of these proteins (see sequences appendix) from the IL3000 strain of Trypanosoma congolense, with the exception of their signal peptide, were made by gene synthesis (Twist Biosciences, USA). All sequences were codon-optimized for expression in human cells. The coding sequences were flanked by unique Notl and Asci sites and cloned into a derivative of the pTT3 expression vector between the leader sequence of the mouse variable light chain 7-33 (Crosnier et al., (2013) Molecular &cellular proteomics : MCP 12, 3976-3986). The ectodomains were expressed as a soluble recombinant protein in HEK293 cells as described (Crosnier et a!., 2013, supra). Protein was purified by Ni2+ immobilised metal ion affinity chromatography using HisTRAP columns (GEHealthcare, UK), eluted in 400mM imidazole as described (Bartholdson et al., (2012) PLoS pathogens 8, e1003031), dialysed into HBS, aliquoted and snap-frozen prior to immunisation. Animals, immunisations, challenge and bioluminescence measurement All animal experiments were performed in accordance with UK Home office legislation and according to local ethical review board approval. Six to eight-week old female BALB / c mice were bred and housed at the Research Support Facility of the Wellcome Trust Sanger Institute. Recombinant proteins were adjuvanted in QuilA and animals immunised subcutaneously with an initial prime followed by two further booster immunisations given at two week intervals. Vaccinated animals were rested for 4 weeks after the final immunisation to mitigate any possible non-specific protective effects elicited by residual adjuvant. Animal challenges were performed using a transgenic form of the T. congolense IL3000 strain genetically engineered to ubiquitously express the firefly luciferase enzyme. Parasites were maintained by weekly passage in wild type BALB / c mice. For infection challenges, bloodstream forms of T. congolense parasites were obtained from the blood of an infected donor mouse at the peak of parasitaemia and between 100 to 1000 parasites were used to infect mice by intravenous injection. From day three post-infection, animals were injected intraperitoneally with luciferase substrate, D-luciferin (D-Luciferin potassium salt, Source BioScience, Nottingham, UK) at a dose of 200 mg / kg, 10 minutes before bioluminescence acquisitions. The mice were anaesthetized with 3% isoflurane and placed in the imaging chamber for analysis. Emitted photons were acquired by a charge coupled device (CCD) camera (IVIS Spectrum Imaging System, Perkin Elmer). Total photons emitted from the image of each mouse were quantified using Living Image software (Xenogen Corporation, Almeda, California), and results were expressed as number of photons / sec / ROI. Immune sera was elicited by subcutaneously immunising a cohort of female BALB / c mice with the purified ectodomain of TclL3000_0_17090 using QuilA as an adjuvant with a prime followed by two booster immunisations separated by two week intervals. Immune sera were collected from immunised mice by cardiac puncture, aliquotted and stored frozen until use. Control sera were taken from unimmunised mice. Immune and control sera were passively transferred to groups of recipient female BALB / c mice by intravenous injection on the day before, on the day, and the day after inoculation with the transgenic T. congolense parasite. Parasitaemia was quantified by bioluminescent imaging using an IVIS instrument. EXAMPLE 2 To discover potential subunit vaccine candidates for T. congolense, the genome sequence was analysed to identify proteins that fulfilled the following criteria: 1) were predicted to encode cell surface proteins that would be accessible to vaccine-elicited host antibodies; 2) did not belong to a paralogous group of parasite proteins that might indicate functional redundancy; 3) contained more than 300 amino acids and so are likely to project beyond the VSG coat on the parasite membrane. Two protein that met these criteria were the related proteins known by their accession numbers TclL3000_0_35140 and TclL3000_0_17090. Results To increase the chances that the extracellular regions of the protein were expressed in a correctly folded conformation and therefore elicit antibodies that would bind to the native parasite protein, we expressed both these proteins using a mammalian expression system to promote the formation of structurally-critical disulphide bonds. The entire ectodomain region was identified and the genes constructed by gene synthesis using codons optimised for expression in human cells. These gene constructs were cloned into a mammalian protein expression plasmid. Human embryonic kidney (HEK)293 cells were transfected with these plasmids and the proteins secreted into the tissue culture medium. The proteins were purified from the tissue culture supernatant by immobilised metal ion chromatography (IMAC) and resolved as a series of glycoforms by SDS-PAGE (Figure 1). Groups of five female BALB / c mice were immunised subcutaneously with the purified ectodomain of TclL3000_0_35140 using a prime followed by two boost regime with the protein adjuvanted with QuilA; control animals were immunised with adjuvant only. Vaccinated animals were challenged with T. congolense parasites delivered intravenously from the blood of an infected donor animal. Animals immunised with Tcll_3000_0_35140 were protected from infection relative to adjuvant-only control mice over the first seven days of infection (Figure 2A, B, C). Two of the five mice immunised with the ectodomain of TclL3000_0_35140 survived the infection challenge beyond day 20. To confirm these results, a larger cohort of 15 mice were immunised with an independent preparation of the TclL3000_0_35140 ectodomain and again all vaccinated animals were protected up to day 9, a time at which all adjuvant-only controls were removed from the study (Figure 3A, B). Thirteen of the fifteen (87%) vaccinated animals showed no evidence of parasitaemia at 25 days post infection (Figure 3A). To further confirm these results, a group of five mice were vaccinated with a different but related protein encoded in the genome of T. congolenese called TclL3000_0_17090. Tcll_3000_0_35140 and Tcll_3000_0_17090 are almost identical in their predicted extracellular region, sharing greater than 98% amino acid identity in their sequence. We again used a protein-in-adjuvant formulation using a prime and two boosts of the protein adjuvanted in QuilA and a control group of five mice receiving adjuvant alone. Again, we observed robust protection of the mice with all vaccinated animals surviving beyond day 10, a time at which all control animals had to be removed from the study (Figure 4A, B, C). To begin to determine the immunological mechanisms of protection and further validate the protective effects of vaccination, we next asked whether animals could be passively protected from infection by the transfer of immune serum from vaccinated animals. To obtain immune sera, a cohort of animals were vaccinated with the purified extracellular region of TclL3000_0_17090 and the immune sera collected; non-immune sera were obtained from unimmunised animals. Animals were dosed with the immune sera by delivering either 100 or 200 microlitres of sera intravenously on three consecutive days and challenged with T. congolense parasite. Those animals receiving immune sera showed reduced levels of parasitameia compared to controls, and showed evidence of a dose-dependent effect (Figure 5). Discussion Animal African trypanosomiasis continues to be a significant impediment in the successful raising of livestock animals in sub-Saharan Africa and previous attempts to vaccinate against the trypanosome parasites that cause this disease have been unsuccessful. Here we have shown that vaccinating animals with a recombinant protein comprising the entire ectodomain of either TclL3000_0_17090 or TclL3000_0_35140 T. congolense cell surface proteins confers protection in a mouse model of infection demonstrating that either protein could be an effective subunit vaccine. We note that the disease is acute in the BALB / c mice used in our infection trials since control mice develop rapid uncontrolled parasitaemia whereas in livestock animals such as goats and cattle the infection is typically a chronic disease with lower parasitaemia suggesting the mouse infection model provides a stringent test of these vaccine candidates. We envisage that a vaccine containing either TclL3000_0_17090 or TclL3000_0_35140 in whole or in part and in the context of an appropriate adjuvant will constitute a vaccine to treat this disease in livestock animals. EXAMPLE 3 The species of parasite known as T. congolense is composed of three recognised strains known as “Savannah”, “Forest” and “Kilifi”. The Savannah strain is generally recognised as the most prevalent and the IL3000 isolate used in the above vaccine screens belongs to this strain. Parasite vaccines, however, are known to show strain-specific protective effects and so to show that the TclL3000_0_35140 and TclL3000_0_17090 vaccine candidates are able to elicit strain-transcending immunity, mice vaccinated with the TclL3000_0_35140 protein were challenged with a strain known as DIN80 which is a “Forest-type” strain. Results & Discussion Mice vaccinated using TclL3000_0_35140 and TelL3000_0_17090 were able to control infection of the “Forest-type” DIN80 strain when compared to controls with one out of nine animals being sterilely protected (Figure 6A, B). Together, these data demonstrate that the TclL3000_0_35140 and TclL3000_0_17090 subunit vaccines are able to elicit crossprotection to different strains of T. congolense. EXAMPLE 4 While T. congolense is a major etiological agent of animal African trypanosomiasis, another species of trypanosome that is genetically very distinct called T. vivax, can also cause this disease. While the geographic distributions of these parasites differ, there is a need to vaccinate livestock animals against both T. congolense and T. vivax. Earlier research by the inventors has already identified a subunit vaccine candidate for T. vivax called invariant flagellum antigen from T. vivax or “IFX” which offers the possibility of vaccinating animals with both proteins to protect both T. congolense and T. vivax. Results & Discussion Three groups of animals were therefore vaccinated with either IFX alone, TclL3000_0_17090 alone or with both proteins using a co-administration procedure. The animals that had been vaccinated with either IFX alone or the IFX-TclL3000_0_17090 combination were first challenged with T. vivax (Figure 7A). We observed that the IFX-vaccinated animals were protected against T. vivax infection as expected, with over half of the animals showing sterile protection. The mice that were vaccinated with both IFX and TclL3000_0_17090 were also able to control the infection with five of the ten animals showing sterile protection (Figure 7A). After waiting 35 days after the challenge with T. vivax to ensure there was no recrudescence, we next challenged all three groups with T. congolense. As expected, the animals vaccinated with IFX showed no protection to T. congolense, and those animals vaccinated with TclL3000_0_17090 alone were able to control a T. congolense infection (Figure 7B). The animals vaccinated with both IFX and TclL3000_0_17090 and which had already survived the T. vivax challenge were also able to control the T. congolense infection, with one animal sterilely protected against challenge with both parasite species (Figure 7B). Together, these data provide evidence that vaccinating animals with both IFX and TclL3000_0_35140 or TclL3000_0_17090 can elicit protection to both T. congolense and T. vivax.

Claims

1. A trypanosomal vaccine comprising an FLA1 binding protein.

2. The trypanosomal vaccine as defined in claim 1, wherein the FLA1 binding protein comprises the amino acid sequence as set forth in SEQ ID NO: 1, or a protein having at least 90% sequence identity to said amino acid sequence, or a fragment of said amino acid sequence thereof, or a nucleic acid molecule encoding said protein.

3. The trypanosomal vaccine as defined in claim 2, comprising a protein which consists of the amino acid sequence as set forth in SEQ ID NO: 1.

4. The trypanosomal vaccine as defined in claim 1, wherein the FLA1 binding protein comprises the amino acid sequence as set forth in SEQ ID NO: 3, or a protein having at least 90% sequence identity to said amino acid sequence, or a fragment of said amino acid sequence thereof, or a nucleic acid molecule encoding said protein.

5. The trypanosomal vaccine as defined in claim 4, comprising a protein which consists of the amino acid sequence as set forth in SEQ ID NO: 3.

6. The trypanosomal vaccine as defined in any one of claims 1 to 5, which is a Trypanosoma congolense vaccine.

7. The trypanosomal vaccine as defined in claim 1, which is a Trypanosoma vaccine and wherein the FLA1 binding protein is selected from a protein of any one of SEQ ID NOs: 5 to 44.

8. The trypanosomal vaccine as defined in claim 1, which is a Leishmania vaccine and wherein the FLA1 binding protein is selected from a protein of any one of SEQ ID NOs: 45 to 60.

9. A pharmaceutical composition comprising a trypanosomal vaccine as defined in any one of claims 1 to 8.

10. The pharmaceutical composition as defined in claim 9, which additionally comprises invariant flagellum antigen.

11. The pharmaceutical composition as defined in claim 10, wherein the invariant flagellum antigen comprises the amino acid sequence as set forth in SEQ ID NO: 61, or a protein having at least 90% sequence identity to said amino acid sequence, or a fragment of said amino acid sequence thereof, or a nucleic acid molecule encoding said protein.

12. The pharmaceutical composition as defined in claim 11, comprising a protein which consists of the amino acid sequence as set forth in SEQ ID NO: 61.

13. The pharmaceutical composition as defined in any one of claims 9 to 12, which additionally comprises one or more adjuvants.

14. The pharmaceutical composition as defined in claim 13, wherein said adjuvant is a saponin adjuvant.

15. The pharmaceutical composition as defined in any one of claims 9 to 14, which additionally comprises a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

16. The pharmaceutical composition as defined in any one of claims 9 to 15, which is adapted for parenteral administration (e.g., intradermal, intramuscular, intravenous and subcutaneous), epidural and mucosal (e.g., intranasal and oral or pulmonary routes or by suppositories).

17. The vaccine composition as defined in any one of claims 9 to 16 for use in a method of preventing or treating trypanosomal infection in a mammal.

18. The vaccine composition for use as defined in claim 17, wherein the trypanosomal infection is an infection mediated by Trypanosoma congolense.

19. The vaccine composition for use as defined in claim 17, wherein the the trypanosomal infection is an infection mediated by Trypanosoma vivax.

20. The vaccine composition for use as defined in any one of claims 17 to 19, wherein the trypanosomal infection is animal African trypanosomiasis (AAT).

21. The vaccine composition as defined in any one of claims 9 to 16 for use in a method of inducing an immune response in a mammal.

22. The vaccine composition for use as defined in any one of claims 17 to 21, wherein the mammal is an ungulate, such as cattle, goats, sheep, horses, pigs and camels.

23. A kit of parts comprising a vaccine composition as defined in any one of claims 9 to 16, a medical instrument or other means for administering the vaccine composition and instructions for use.

Images